bismuth has been researched along with metronidazole in 445 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (0.90) | 18.7374 |
1990's | 215 (48.31) | 18.2507 |
2000's | 95 (21.35) | 29.6817 |
2010's | 76 (17.08) | 24.3611 |
2020's | 55 (12.36) | 2.80 |
Authors | Studies |
---|---|
Katelaris, P | 1 |
Burette, A; Glupczynski, Y | 1 |
Bell, GD; Powell, K | 1 |
Seppälä, K | 1 |
Cheng, A; Chung, SC; Hosking, SW; Leung, JW; Li, AK; Ling, TK; Yung, MY | 1 |
Jaskiewicz, K; Lastovica, A; Le Roux, E; Louw, JA; Lucke, W; Marks, IN; Winter, T; Zak, J | 1 |
Adeyemi, EO; al-Homsi, M; Boehme, D; Fadlalla, H; Goodwin, S; Nnalue, NA; Sim, AJ | 1 |
Corbishley, CM; Goggin, PM; Jackson, PA; Marrero, JM; Northfield, TC; Spychal, RT | 1 |
Laine, L | 2 |
Berstad, A; Berstad, K; Hundal, O; Wilhelmsen, I | 1 |
Bell, GD; Bolton, G; Brooks, S; Burridge, SM; Gant, PW; Harrison, G; Powell, KU; Prosser, S; Purser, K; Spencer, G | 1 |
Beattie, S; Keane, C; O'Morain, C; Patchett, S | 1 |
Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Saeed, ZA | 1 |
Andrews, P; Borody, TJ; Brandl, S; Devine, M; George, LL; Lenne, J; Moore-Jones, D; Walton, M | 1 |
Börsch, G; Labenz, J | 2 |
Alpert, LC; Evans, DG; Evans, DJ; Genta, RM; Graham, DY; Klein, PD; Lew, GM; Malaty, HM | 1 |
Beattie, S; Keane, C; Leen, E; O'Morain, C; Patchett, S | 1 |
Bär, W; Gebel, M; Haruma, K; Lange, P; Müller, MJ; Schorn, T; Soudah, B; Varrentrapp, M; Wagner, S | 1 |
Chittajalu, R; Dahill, SW; el Nujumi, AM; Fullarton, GM; Hilditch, TE; MacDonald, AM; McColl, KE | 1 |
Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM | 1 |
Lyall, JB | 1 |
Lee, FD; Nakshabendi, IM; Peebles, SE; Russell, RI | 1 |
Korsten, MA; Lateef, SK; Lieber, CS; Paronetto, F; Uppal, R | 1 |
Keane, C; Mathai, E; McKenna, D; O'Morain, C; O'Riordan, T; Sweeney, E; Tobin, E | 1 |
Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM; Opekun, A | 1 |
Axon, AT | 2 |
Appelman, H; Barnett, JL; Behler, EM; Elta, GH; Kern, S; Murphy, R; Nostrant, TT | 1 |
Börsch, G; Rühl, GH | 1 |
Dent, J; McNulty, CA; Wise, R | 1 |
Anver, MR; Battles, JK; Blumenauer, LL; Gonda, MA; Gorelick, PL; Haines, DC; Russell, RJ; Ward, JM | 1 |
Alvarez Baleriola, I; Boixeda, D; de Rafael, L; Gisbert, JP; Martín de Argila, C; Vila, T | 1 |
Alvarez Baleriola, I; Bermejo, F; Boixeda, D; de Rafael, L; García Plaza, A; Gisbert, JP; Martín de Argila, C | 1 |
Becker, T; Börsch, G; Köhl, H; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B | 1 |
Dettmer, A; Domschke, W; Fenner, T; Gregor, M; Hesse, P; Holtmann, G; Miederer, SE; Schentke, KU; Schütz, E; van Husen, N | 1 |
Wilson, WH | 1 |
Contreras, L; Giglio, M; Hoffenberg, P; Ossa, P; Reyes, V; Weitz, JC | 1 |
Folwaczny, C | 1 |
Foltz, CJ; Fox, JG; Shames, B; Yan, L | 2 |
Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Nesje, LB; Wilhelmsen, I | 1 |
Appelman, HD; Barnett, JL; Behler, EM; Crause, I; Elta, GH; Nostrant, TT; Scheiman, JM | 1 |
Asnicar, MA; Chong, SK; Croffie, JM; Fitzgerald, JF; Lee, CH; Lou, Q; Zimmerman, SE | 1 |
de Boer, WA; Tytgat, GN | 2 |
Fennerty, MB | 2 |
Beattie, S; Gilvarry, J; Hamilton, H; Keane, CT; O'Morain, CA; Sweeney, EC; Xia, HX | 1 |
Blecker, U; Hart, J; Kirschner, BS; McKeithan, TW | 1 |
Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S | 1 |
Cheng, AF; Chung, SC; Leung, VK; Li, AK; Ling, TK; Suen, R; Sung, JJ | 1 |
de Graaf, B; Thijs, JC; van Zwet, AA | 1 |
Cohen, MH | 1 |
Clyne, M; Daly, LE; Drumm, B; Durnin, MT; Gormally, SM; Kierce, BM; Prakash, N | 1 |
Klotz, O; Treiber, G | 1 |
Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
de Boer, WA; Driessen, WM | 1 |
Berstad, A; Wilhelmsen, I | 1 |
Rune, SJ | 1 |
Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K | 1 |
Giannikos, N; Kalogeropoulos, N; Karameris, A; Mavrogeorgis, A; Papatheodorou, G; Rokkas, T | 1 |
Banerjee, S; el-Omar, E; McColl, KE | 1 |
Dhillon, AP; Fraser, AG; Pounder, RE; Sankey, EA; Sim, R | 1 |
Marshall, BJ | 1 |
Bertrams, J; Börsch, G; Labenz, J; Rühl, GH | 1 |
Lee, WY; Lin, JT; Wang, JT; Wang, TH; Wu, MS; Yang, JC | 1 |
Asaka, M; Horita, S; Inoue, K; Kato, M; Kimura, T; Kudo, M; Meguro, T; Ohtaki, T | 1 |
Bang, CJ; Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Hjartholm, AS; Hundal, O; Nesje, LB; Nysaeter, G; Wilhelmsen, I | 1 |
de Boer, WA; Driessen, WM; Potters, VP; Tytgat, GN | 1 |
Campbell, DR; Cherian, R; McGregor, DH; Weston, AP | 1 |
Berstad, A; Berstad, K; Sjödahl, R | 1 |
Dent, J; Eyre-Brook, IA; Lobo, AJ; McNulty, CA; Uff, JS; Wilkinson, SP | 1 |
Graham, DY; Peura, DA | 1 |
Bleck, J; Gebel, M; Gladziwa, U; Haruma, K; Manns, M; Schmidt, H; Soudah, B; Wagner, S | 1 |
Boixeda, D | 1 |
Martínez, MJ | 1 |
Corinaldesi, R; De Giorgio, R; Gasperoni, S; Paparo, GF; Poli, L; Stanghellini, V; Tucci, A; Varoli, O | 1 |
Reilly, TG; Walt, RP | 1 |
Chang, FY; Chen, TS; Lee, SD; Tsay, SH | 1 |
Berman, D; George, J; Groisman, GM; Harpaz, N | 1 |
Correa, P; Fontham, ET; Hunter, FM; Johnson, WD; Malcom, GT; Rood, JC; Ruiz, B; Sobhan, M | 1 |
Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I | 1 |
Berstad, A; Berstad, K | 1 |
Brazer, SR; Maniatis, AG | 1 |
Genta, RM; Go, MF; Graham, DY; Lew, GM; Rehfeld, JF | 1 |
Correa, P; Fontham, E; Hunter, FM; Ruiz, B; Samloff, IM; Sobhan, M | 1 |
Hammar, CH; Jaspersen, D | 1 |
Kihira, K; Kimura, K; Sato, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
Graham, DY; Hepps, KS; Lew, GM; Ramirez, FC; Saeed, ZA | 1 |
Börsch, G; Gyenes, E; Labenz, J; Rühl, GH | 2 |
Andrews, P; Borody, TJ; Carroll, M; Ferch, N; Jankiewicz, E | 1 |
Calam, J; Moss, SF | 1 |
Asaka, M; Inoue, K; Kato, M; Kimura, T; Kudo, M; Meguro, T; Miyazaki, T | 1 |
Cutler, AF; Schubert, TT | 2 |
Della Casa, G; Di Gregorio, C; Ferrari, AM; Frazzoni, M; Grisendi, A; Lonardo, A; Melini, L; Pulvirenti, M | 1 |
Kanayama, S; Matsuzawa, Y; Nakanishi, T; Shinomura, Y | 1 |
Genta, RM; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Ramirez, FC | 1 |
Jaskiewicz, K; Louw, JA; Marks, IN | 1 |
Boixeda, D; Gisbert, JP; Hernández Ranz, F; Martín de Argila, C | 1 |
Karita, M; Nakazawa, T; Okita, K; Sugiyama, T; Tsuda, M | 1 |
Soll, AH | 1 |
Fennerty, MB; Vakil, N | 1 |
Davis, S | 1 |
Bang, CJ; Berstad, A; Berstad, K; Hatlebakk, JG; Hausken, T; Hundal, O; Nesje, LB; Nysaeter, G; Olafsson, S; Tefera, S | 1 |
Alvarez Baleriola, I; Boixeda, D; de Rafael, L; García Plaza, A; García, M; Gisbert, JP; Martín de Argila, C | 1 |
Acuña, R; Albornoz, V; Figueroa, G; Portell, DP; Toledo, MS; Troncoso, M; Vigneaux, J | 1 |
Alkan, S; Cohen, P; Karcher, DS; Newman, MA | 1 |
Bell, GD; Powell, KU | 1 |
Satoh, K | 1 |
Bermejo, F; Boixeda, D; de Rafael, L; Gisbert, JP; Martín de Argila, C; Redondo, C | 1 |
Bergseth, M; Berstad, A; Berstad, K; Hundal, O; Olafsson, S; Tefera, S; Wilhelmsen, I | 1 |
Gabryelewicz, A | 1 |
de Boer, WA; Driessen, WM; Jansz, AR; Tytgat, GN | 1 |
de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ | 1 |
Cilleruelo Pascual, ML; Echávarri Olavarría, F; Manzanares López-Manzanares, J; Medina Benítez, E; Molina Arias, M; Román Riechman, E; Urruzuno Tellería, P | 1 |
De Boer, WA; Driessen, WM; Tytgat, GN | 1 |
Braga, PC; Brenciaglia, MI; Dubini, F; Fornara, AM; Scaltrito, MM | 1 |
Dammann, HG | 1 |
De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY | 1 |
Beastall, G; Beattie, AD; Morton, R; Park, RH; Taha, AS | 1 |
Behler, EM; Chey, WD; Crause, I; Elta, GH; Scheiman, JM | 1 |
Daróczy, J; Ferenczi, K; Kalas, D; Pálos, G; Prónai, L | 1 |
Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y | 1 |
Goh, KL; Navaratnam, P; Peh, SC | 1 |
Carmichael, JM; Patchin, GM; Wieland, KA | 1 |
Freston, JW; Murphy, K; Taylor, JL; Zagari, M | 1 |
Harris, A; Misiewicz, JJ | 1 |
Scott, BB; Vautier, G | 1 |
de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ | 1 |
Seifrit, B | 1 |
Choi, CH; Chung, EC; Kung, NN; Kwok, SP; Li, TH; Lim, BH; Ma, HC; Ng, PW; Sung, JJ; Wong, KC; Yuen, NW | 1 |
Biasco, G; Paparo, GF; Tucci, A | 1 |
Agrawal, BK; Dayal, VM; Kamal, J; Kumar, P; Shahi, SK | 1 |
Aubert, E; Berge, T; Efskind, PS; Haug, JB; Hauge, T; Henriksen, M; Lerang, F; Moum, B; Nicolaysen, K; Odegaard, A; Ragnhildstveit, E; Søberg, T; Tolås, P | 1 |
Peterson, WL | 1 |
Drumm, B; Durnin, M; Goggin, N; Moriarty, S; Rowland, M; Walsh, D | 1 |
Damianos, AJ; McGarrity, TJ | 1 |
Forbes, GM | 1 |
Fock, KM | 1 |
Lee, SD; Lin, HJ; Lo, WC; Perng, CL; Wang, K | 1 |
Beattie, S; Buckley, MJ; Gilvarry, J; Hamilton, H; O'Morain, CA | 1 |
Angeletti, S; Annibale, B; Bordi, C; Delle Fave, G; Malagnino, F; Mancino, C; Marignani, M | 1 |
Kim, MJ; Michener, R; Triadafilopoulos, G | 1 |
Myers, D | 1 |
Hogan, J; Krasner, N; Lombard, M; Purkayastha, SK; Tan, WC | 1 |
Bisso, G; Caroli, M; Celle, G; Mansi, C; Mela, GS; Mele, MR; Olivieri, A; Saggioro, A; Savarino, V; Termini, R; Tosatto, R; Vigneri, S | 1 |
Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM | 1 |
Chan, CS; Chan, FK; Chung, SC; Lee, YT; Leung, VK; Li, EK; Sung, JJ; To, KF; Woo, J; Yung, MY | 1 |
El-Zaatari, F; Engstrand, L; Genta, RM; Graham, D; Scheynius, A | 1 |
el-Zimaity, HM; Graham, DP; Graham, DY; Hoffman, J; Osato, M | 1 |
Eaton, KA; Kramer, LW; Wack, RF | 1 |
Malfertheiner, P; Mégraud, F | 1 |
Keller, JJ; Rauws, EA; Tytgat, GN; van der Hulst, RW | 1 |
Batchelder, M; Fox, JG; Hayward, A; Murphy, JC; Palley, L; Shames, B; Yan, L | 1 |
Bierman, JC; Blanchard, TG; Czinn, SJ; Diters, RW; Leunk, RD | 1 |
Cheng, AF; Chung, SS; Ling, TK; Sung, JJ; Yiu, PY | 1 |
Emami, S; Estrada, R; Laine, L; Trujillo, M | 1 |
Carrazco, J; Checkley, W; Cordero, L; Gilman, RH; Leon-Barua, R; McDonald, J; Ramirez-Ramos, A; Recavarren-Arce, S; Salazar, G; Valdez, Y; Watanabe, J | 1 |
Bielański, W; Bobrzyński, A; Budzyński, A; Gedliczka, O; Konturek, S; Stachura, J | 2 |
Donnelly, C; McDowell, S; McLaren, A; Williamson, R | 1 |
Bolin, TD; Engelman, JL; Korman, MG; Pianko, S | 1 |
Chan, FK; Cheng, AF; Chung, SC; Lau, JY; Lee, YT; Leung, VK; Leung, WK; Ling, TK; Ng, EK; Suen, R; Sung, JJ | 1 |
Berge, T; Haug, JB; Henriksen, M; Lerang, F; Moum, B; Ragnhildstveit, E; Sandvei, PK; Tolås, P; Whist, JE | 1 |
Bardhan, KD; Jahnsen, J; Lotay, N; Marcelino, M; Roberts, PM; Wurzer, H | 1 |
Ducóns, JA; Fuentes, J; García, S; Gimeno, L; Gomollón, F; Montoro, M; Vera, J | 1 |
Calvet Calvo, X | 1 |
Brullet, E; Calvet, X; Campo, R; Comet, R; García, N; Navarro, M | 1 |
Ara, JR; Bertol, V; Brieva, L; Canellas, A; del Agua, C | 1 |
Fitzgerald, JF; Troncone, R | 1 |
de Boer, WA; Haeck, PW; Mulder, CJ; Otten, MH | 1 |
Ahsan, K; Hadjiyane, C; Karakurum, A; Mohammed, I; Nawaz, A; Pellecchia, C | 1 |
Fendrick, AM; Jeffries, MA; Scheiman, JM | 1 |
Bashirova, ES; Butorov, IL; Darvin, VV; Lokhvitskiĭ, SV; Proshin, AV | 1 |
Butruk, E; Dziurkowska-Marek, A; Hennig, E; Kohut, M; Marek, T; Nowak, A; Ostrowski, J; Przytulski, K; Regula, J | 1 |
Kleibeuker, JH; Kooy, A; Thijs, JC; van der Wouden, EJ; van Zwet, AA | 1 |
Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB | 1 |
Alarcón, T; Domingo, D; López-Brea, M; Prieto, N; Sánchez, I | 1 |
Kashifard, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Siavoshi, F | 1 |
Bardhan, KD; Duggan, AE; Gudjonsson, H; Hoie, O; Kliebe-Frisch, C; Kristensen, ES; Pipkin, GA; Schuetz, E | 1 |
Coudron, PE; Stratton, CW | 1 |
Bellin, EY; Fletcher, DD; Shuter, J; Simone, VJ | 1 |
Chang, MH; Hsu, HY; Huang, FC; Lee, PI; Shun, CT | 1 |
Biagini, R; Bilardi, C; Bisso, G; Celle, G; Mansi, C; Mele, MR; Pivari, M; Savarino, V; Termini, R; Vigneri, S; Zentilin, P | 1 |
Eshraghi, J; Fassihi, R; Yang, L | 1 |
Chua, AB; Cutler, A; Ding, RP; Goh, KL; Kandasami, P; Mazlam, MZ; Raj, SM | 1 |
Ozbakir, O; Turasan, A; Utaş, C; Utaş, S | 1 |
Choi, CH; Kung, NN; Lai, WM; Lam, KN; Leung, EM; Li, TH; Lui, YH; Ng, PW; Sung, JJ; Yuen, NW | 1 |
Kabala, A; Pawłowski, W; Petsch, B | 1 |
Kleibeuker, JH; Kooy, A; Thijs, JC; Van der Wouden, EJ; Zwet, AA | 1 |
Fennerty, MB; Kelly, C; Knigge, K; Peterson, WL | 1 |
Marshall, JB | 1 |
Blanchard, J; Boden, J; Ermak, T; Georgakopoulos, K; Giannasca, P; Gray, H; Hill, J; Ingrassia, J; Kleanthous, H; Lee, CK; Monath, TP; Soike, K; Tibbitts, T; Weltzin, R | 1 |
Ashktorab, H; Hinds, T; Jagtap, J; Kim, KS; Scott, VF; Smoot, DT | 1 |
Cave, DR; Hoffman, JS; Katz, LM | 1 |
Bang, CJ; Berstad, A; Coll, P; Hatlebakk, JG; Hausken, T; Nysaeter, G; Olafsson, S; Olafsson, T; Tefera, S | 1 |
Hirschowitz, BI; Mönkemüller, KE | 1 |
Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Chodash, HB; Dawson, BK; Luca, S; Michalos, A; Terranova, R | 1 |
Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H | 1 |
Choe, YH; Hong, YC; Kim, SK; Lee, DH; Pai, SH; Son, BK | 1 |
Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M | 1 |
Berstad, A; Hatlebakk, JG; Tefera, S | 1 |
Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL | 1 |
Neiger, R; Schmassmann, A; Seiler, G | 1 |
de Boer, WA | 2 |
Dashti, M; Massarrat, S; Pahlewanzadeh, MR; Roghani, HS | 1 |
Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Suen, R; Sung, JJ; Wu, JC | 1 |
Angeles Arpa, M; Bermejo, F; Boixeda, D; García Arata, I; García Plaza, A; Gisbert, JP; Jesús Higes, M; Martín de Argila, C; Nieves Rincón, M | 1 |
Carpio, D; Gisbert, JL; Gisbert, JP; Grávalos, RG; Marcos, S; Pajares, JM | 1 |
Canning, A; Egan, C; Farraye, FA; Kemp, JA; Lee, M; Tataronis, G | 1 |
Mach, T; Zahradnik-Bilska, J | 1 |
Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y | 1 |
Alonso García, I; García Pérez, A; Giménez Samper, M; Valverde de La Osa, J | 1 |
De Boer, WA; Jansen, JB; Schneeberger, PM; Van De Wouw, BA; Van Etten, RJ; Van Oijen, AH | 1 |
Gurer, I; Hilmioglu, F; Ozyilkan, E; Sare, M; Taskin, V | 1 |
Bravo, JC; Bravo, LE; Correa, P; Realpe, JL; Ruiz, B; van Doorn, LJ | 1 |
Brousal, A; Kearney, DJ | 1 |
Barkun, AN; Beech, R; Best, L; Fallone, CA; Friedman, G; Joseph, L; Loo, V; Mayrand, S | 1 |
Bisson, S; Bojarski, C; Epple, HJ; Fromm, M; Kirstein, FW; Riecken, EO; Schulzke, JD | 1 |
Jewell, D; McLeod, R; Sandborn, W | 1 |
Anderson, SY; El-Zimaity, HM; Graham, DY; Hoffman, J; Kwon, DH; Opekun, AR; Osato, MS | 1 |
Chmiela, M; Czkwianianc, E; Lawnik, M; Płaneta-Małecka, I; Rudnicka, W | 1 |
Bilardi, C; Bisso, G; Borgonovo, G; Borro, P; De Salvo, L; Dulbecco, P; Mansi, C; Pivari, M; Raffaella Mele, M; Savarino, V; Tessieri, L; Vigneri, S; Zentilin, P | 1 |
Buzás György, M; Illyés, G; Székely, E; Széles, I | 1 |
Ching, CK; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, WM | 1 |
Cooper, R; Miskovitz, P; Nagler, J | 1 |
Lam, SK; Wang, WH; Wong, BC | 1 |
Mégraud, F | 1 |
Baena Díez, JM; García Lareo, M; López Mompó, C; Rams Rams, F; Rosario Hernández Ibáñez, M; Teruel Gila, J | 1 |
Chan, CK; Chu, KM; Fung, FM; Hu, WH; Lai, KC; Lam, SK; Lau, GK; Leung, SY; Wang, WH; Wong, BC; Wong, WM; Yuen, MF; Yuen, ST | 1 |
El-Zimaity, HM; Graham, DY; Hoffman, J; Kwon, DH; Osato, MS; Saeed, MA | 1 |
Bravo, JC; Bravo, LE; Casabon, AL; Collazos, T; Correa, P; Fischbach, LA; Ramirez, H; Realpe, JL; Ruiz, B; Schmidt, BA | 1 |
Hopkins, RJ | 1 |
Delves, HT; Doig, LA; Phillips, RH; Powell, JJ; Sieniawska, CE; Thompson, RP; Whitehead, MW | 1 |
Gisbert, JL; Gisbert, JP; Marcos, S; Pajares, JM | 2 |
Bardhan, KD; Mitchell, TR; Morris, P; Morton, D; Perry, MJ; Roberts, PM; Rowland, A; Sanders, DS; Thompson, M | 1 |
Bayerdörffer, E; Graham, DY; Miehlke, S | 1 |
Ananthakrishnan, N; Badrinath, S; Kate, V | 1 |
Amini, M; Kamalian, N; Kaviani, MJ; Malekzadeh, R; Massarrat, S; Sotoudeh, M; Vahedi, H | 1 |
Daroch, F; García, A; González, C; Kawaguchi, F; Rivera, N; Solar, H; Vega, E | 1 |
Beales, IL | 1 |
Burm, M; Faigel, D; Fennerty, MB; Kelly, C; Magaret, N; Peterson, W | 1 |
Doulgeroglou, V; Kamberoglou, D; Patra, E; Polymeros, D; Sanidas, I; Savva, S; Tzias, V | 1 |
Corder, FA; Howden, CW; Sahai, AV; Sharma, VK | 1 |
Artikis, V; Georgopoulos, SD; Karatapanis, S; Ladas, SD; Mentis, A; Raptis, SA; Spiliadi, C; Triantafyllou, K | 1 |
Amsler, KM; Foster, LA; Merrill, JJ; Modzelewski, TC; Quispe, JD; Sizemore, CF; Slee, AM; Stevenson, DA | 1 |
Takahashi, S; Tanaka, A | 1 |
Ohkusa, T; Sato, N | 1 |
Gisbert, JP; Pajares, JM | 1 |
Ammon, S; Klotz, U; Malfertheiner, P; Treiber, G | 1 |
Bermejo, F; Boixeda, D; Defarges, V; García-Plaza, A; Hernández-Ranz, F; López-Sanromán, A; Martín-De-Argila, C; Milicua, JM | 1 |
Bago, J; Bevanda, M; Bilić, A; Halle, ZB; Jandrić, D; Kućisec, N; Strinić, D; Tomić, M | 1 |
Chan, CK; Fung, FM; Ho, VY; Hu, WH; Hung, WK; Lai, KC; Lam, SK; Szeto, ML; Tong, TS; Wong, BC; Wong, GS; Wong, WM; Xia, HH; Yip, AW; Yuen, MF | 1 |
Farup, PG; Høie, O; Lange, OJ; Tholfsen, J; Torp, R; Wetternus, S | 1 |
Berstad, A; Hatlebakk, JG; Olafsson, S | 1 |
Borody, T; Dallaire, C; De Boer, WA; Fallone, CA; Farley, A; Mégraud, F; O'Morain, C; Piotrowski, J; Schuman, R; Spénard, J; Tytgat, G | 1 |
Azagra, R; Calvet, X; Gené, E; Gisbert, JP | 1 |
Nurbaev, FE; Orziev, ZM; Rakhimova, GSh | 1 |
Correa, P; Feldman, M; Fischbach, LA; Fontham, E; Goodman, KJ; Jain, R; Priest, E | 1 |
Dore, MP; Graham, DY; Manca, A; Maragkoudakis, E; Marras, L; Nieddu, S; Realdi, G | 1 |
Bästlein, E; Bayerdörffer, E; Haferland, C; Jacobs, E; Kirsch, C; Lehn, N; Miehlke, S; Neumeyer, M; Papke, J; Schneider-Brachert, W; Stolte, M; Vieth, M | 1 |
de Boer, SY; de Boer, WA; Siem, H; v d Meeberg, PC | 1 |
Cisneros, G; Gurney, M; Jarjoura, D; Lara, LF; Moauro, B; Polen, A; Rutecki, G; Van Ness, M; Whittier, F | 1 |
Andriulli, A; Barberani, F; Festa, V; Merla, A; Perri, F; Pilotto, A | 1 |
Bianchi Porro, G; Cucino, C; Parente, F | 1 |
Furne, JK; Levitt, MD; Madoff, RD; Ohge, H; Springfield, J; Sueda, T | 1 |
Berge, T; Berstad, A; Henriksen, TH; Lerang, F; Lia, A; Ragnhildstveit, E; Schøyen, R; Thoresen, T; Tveten, Y | 1 |
de Boer, WA; Kuipers, EJ; Kusters, JG | 1 |
Abudayyeh, S; Belson, G; Dore, MP; El-Zimaity, HM; Graham, DY; Osato, MS | 1 |
Altintaş, E; Aydin, O; Camdeviren, H; Sezgin, O; Ulu, O | 1 |
Calvet, X; Gené, E; Güell, M; Montserrat, A; Vergara, M | 1 |
Choi, JH; Choung, RS; Chun, HJ; Han, WS; Hyun, JH; Jeen, YT; Jung, SW; Keum, B; Kim, CD; Kim, YS; Lee, HS; Lee, SW; Park, SC; Ryu, HS; Um, SH | 1 |
de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ | 1 |
Dickason, J; Fischbach, LA; van Zanten, S | 1 |
Filik, L; Köksal, AS; Odemiş, B; Ozden, A; Parlak, E; Sahin, B; Saşmaz, N; Ulker, A; Yolcu, OF | 1 |
Shao, Y; Wang, YS; Yang, H; Yu, ZL; Zhang, L; Zhang, ST | 1 |
Calvet, X; Carpio, D; Fuentes, J; Gisbert, JP; Guardiola, J; Olivares, D; Tito, L; Tomas, A | 1 |
Shao, Y; Yu, ZL; Zhang, L; Zhang, ST | 1 |
Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, DH; Lee, JH; Park, MJ; Song, IS | 1 |
Aumais, C; Brunet, JS; Grace, M; Lefebvre, M; Massicotte, J; Spénard, J; Tremblay, C | 1 |
Pan, Y; Xiao, SD; Zhang, L; Zheng, Q | 1 |
Borody, TJ | 1 |
Fukuda, Y; Sakagami, T | 1 |
Bray, R; Hiratsuka, H; Hiratsuka, T; Kimura, K; Suzuki, T; Tamura, K | 1 |
Benito, LM; Bermejo, F; Bory, F; Castro-Fernández, M; Cosme, A; Ducons, J; Fernández-Bermejo, M; Gisbert, JP; Lamas, E; López-Rivas, L; Olivares, D; Pabón, M; Pérez-Aisa, A | 1 |
Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P | 1 |
Kerton, A; Warden, P | 1 |
Altintaş, E; Sezgin, O; Tataroğlu, C; Uçbilek, E | 1 |
Cheon, JH; Jung, HC; Kim, JM; Kim, JS; Kim, N; Kim, SG; Lee, DH; Song, IS | 1 |
Pistiolas, D; Robotis, J; Rokkas, T; Sechopoulos, P | 1 |
Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR | 1 |
Choe, YH; Choi, J; Jang, JY; Kim, JS; Kim, KM; Park, HY | 1 |
Kadayifçi, A | 1 |
Mahachai, V; Thong-Ngam, D | 1 |
Bagci, S; Ilgan, S; Kadayifci, A; Safali, M; Uygun, A | 1 |
Bravo, JC; Bravo, LE; Camargo, MC; Ceron, C; Correa, P; Delgado, AG; Fontham, ET; Mera, RM; Piazuelo, MB; Yepez, MC | 1 |
Buzás, GM; Széles, I | 1 |
Baker, DE | 1 |
Dunzendorfer, T; Johnson, R; Wilkins, S | 1 |
Balkarli, A; Baştürk, A; Cerçi, S; Senol, A; Songür, Y | 1 |
Derakhshan, F; Haghazali, M; Mirsattari, D; Mohsenian, N; Molaei, M; Talaie, R; Zali, MR; Zojaji, H | 1 |
Kandulski, A; Malfertheiner, P; Selgrad, M | 1 |
O'Connor, HJ; O'Morain, CA; Qasim, A; Saleem, A | 1 |
Chey, WD; Higgins, PD; Luther, J; Moayyedi, P; Schoenfeld, PS; Vakil, N | 1 |
Amini, M; Tajik, A | 1 |
Choe, YH; Chung, IS; Kim, HS; Kim, JI; Kim, JJ; Kim, N | 1 |
Classen, M; Liu, W; Ma, J; Pan, K; Winawer, S; You, W; Zauber, A; Zhang, L; Zhao, H; Zhou, T | 1 |
Hwang, JH; Hwang, TJ; Jeong, SH; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Park, YS; Song, IS | 1 |
Hibi, T; Nishizawa, T; Suzuki, H | 1 |
Demir, M; Göktürk, S; Oztürk, NA; Serin, E; Yilmaz, U | 1 |
Bytzer, P; Dahlerup, JF; Eriksen, JR; Jarbøl, DE; Rosenstock, S; Wildt, S | 1 |
Gisbert, JP | 1 |
Astegiano, M; Cisarò, F; De Angelis, C; Pellicano, R; Rizzetto, M; Saracco, G | 1 |
Choi, KD; Chung, JW; Jung, HY; Kim, JH; Lee, GH; Lee, JH; Oh, TH; Song, HJ; Yun, SC | 1 |
Cuccu, M; Dore, MP; Farina, V; Graham, DY; Mameli, L; Massarelli, G | 1 |
Choi, JH; Hyun, JJ; Jung, SW; Kim, JH; Kim, SY; Koo, JS; Kwon, BS; Lee, SK; Lee, SW; Park, JY; Yim, HJ | 1 |
Chuah, SK; Hsu, PI; Tsay, FW; Wu, DC | 1 |
Başer, O; Emer, O; Kadayifci, A; Kantarcioğlu, M; Kılcıler, G; Ozcan, A; Polat, Z; Uygun, A | 1 |
Agah, S; Ekhlasi, G; Ghourchian, S; Salehpour, A; Shidfar, F | 1 |
Cardenas, VM; Dominguez, DC; Graham, DY; Reddy, RK; Salazar, CO; Snyder, LK | 1 |
Liang, X; Liu, W; Lu, H; Sun, Q; Xiao, S; Xu, X; Zhang, W; Zheng, Q | 1 |
Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M | 1 |
Gisbert, JP; Marin, AC; McNicholl, AG | 1 |
Graham, DY; Lee, YC; Wu, MS | 1 |
Ecker, T; Krieger, T; Leandro, G; Malfertheiner, P; Venerito, M | 1 |
Jang, JY; Jung, HK; Kim, CG; Kim, SG; Lee, H; Lee, HL; Lee, YC; Shin, ES; Shin, WG | 1 |
Dong, S; Feng, J; Hu, L; Li, Y; Sun, J; Yu, C | 1 |
Ang, TL; Song, M | 1 |
Ding, L; Huang, NY; Li, WB; Liu, B; Wen, AD; Wu, Y | 1 |
Jo, HJ; Kim, N; Lee, DH; Lee, ST; Lim, JH; Park, YS; Shin, CM; Song, IS | 1 |
Aisa, AP; Barrio, J; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Gisbert, JL; Gisbert, JP; Marcos, S; Marín, AC; McNicholl, AG; Modolell, I; Molina-Infante, J; Rodrigo, L | 1 |
Malfertheiner, P; Selgrad, M | 1 |
Lv, ZF; Wang, B; Wang, H; Wang, YH; Xie, Y; Xiong, HF; Yang, Y | 1 |
Cao, Z; Chen, Q; Liang, X; Liao, J; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
Aktaş, B; Başyiğit, S; Kefeli, A; Nazlıgül, Y; Uzman, M; Yeniova, AÖ | 1 |
Bair, MJ; Hsu, PI; Hsu, WH; Hu, CT; Hu, HM; Jheng, GH; Kuo, CH; Kuo, FC; Liu, CJ; Shih, HY; Wu, DC; Wu, IC; Wu, MC | 1 |
Bai, P; He, L; Li, Y; Lin, S; Qian, J; Song, Z; Wang, Y; Xue, Y; Zhang, J; Zhou, L | 1 |
Ataseven, H; Baglıcakoglu, M; Biyik, M; Demir, A; Goktepe, H; Gungor, G; Kayacetin, E; Ucar, R | 1 |
Annibale, B; Calabrese, C; Caselli, M; Di Mario, F; Farinati, F; Gasbarrini, G; Gullini, S; Ierardi, E; Luzza, F; Maconi, G; Ojetti, V; Pretolani, S; Romano, M; Rugge, M; Savio, A; Stockbrugger, R; Zagari, RM | 1 |
Akhtar, N; Asif, HM; Sugiyama, T; Usmanghani, K; Zaidi, SF | 1 |
Graham, DY; Lee, SY | 1 |
Chaithongrat, S; Gamnarai, P; Mahachai, V; Namtanee, J; Prapitpaiboon, H; Vilaichone, RK; Wongcha-um, A | 1 |
Chen, Q; Graham, DY; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
Asilturk, Z; Basyigit, S; Hokkaomeroglu, M; Kefeli, A; Nazligul, Y; Sapmaz, F; Uzman, M; Yeniova, AO | 1 |
Aslan, M; Basyigit, S; Kefeli, A; Kefeli, TT; Tanas, O; Yeniova, AO | 1 |
Bai, P; He, L; Song, Z; Xue, Y; Zhang, J; Zhou, L | 1 |
Arnold, CA; Coss, E; Cryer, B; Doern, CD; Dunbar, KB; Lam-Himlin, DM; Mitui, M; Okwara, C; Park, JY; Thung, I; Valasek, MA | 1 |
Dore, MP; Graham, DY | 1 |
Chiba, N; Fallone, CA; Fischbach, L; Gisbert, JP; Hunt, RH; Jones, NL; Leontiadis, GI; Marshall, JK; Moayyedi, P; Render, C; van Zanten, SV | 1 |
Amorena, E; Campillo, A; Kutz, M; La Iglesia, M; Ostiz, M | 1 |
Fallone, CA; Shaikh, T | 1 |
Chen, Q; Fu, Q; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
Lin, JT; Liou, JM; Wu, MS | 1 |
Chey, WD; Howden, CW; Leontiadis, GI; Moss, SF | 1 |
Baldassarre, G; Boscariolo, L; De Bastiani, R; De Polo, M; Di Mario, F; Elisei, W; Ferronato, A; Franceschi, M; Grillo, S; Landi, S; Picchio, M; Tursi, A; Zamparella, M | 1 |
Jung, K; Kim, HK; Kim, JH; Kim, SE; Lee, YD; Moon, W; Park, MI; Park, SJ | 1 |
Hu, Y; Lu, NH; Zhu, Y | 2 |
Akay, S; Akpinar, Z; Unsal, B | 1 |
Ang, TL; Aung, MM; Chakravuth, O; Chotivitayatarakorn, P; Fock, KM; Goh, KL; Graham, D; Harnsomburana, P; Kositchaiwat, C; Lee, YC; Leelakusolvong, S; Leow, A; Mahachai, V; Mairiang, P; Maneerattanaporn, M; Mya, SM; Pisespongsa, P; Pittayanon, R; Rani, A; Rasachak, B; Rojborwonwitaya, J; Sansak, I; Sollano, JD; Sugano, K; Syam, AF; Treeprasertsuk, S; Trong Quach, D; Vannarath, S; Vilaichone, RK; Wiwattanachang, O; Yamaoka, Y | 1 |
Alvaro, D; Bellesia, A; Brambilla, G; Bresci, G; D'Angelo, A; De Francesco, V; Di Ciaula, A; Eramo, A; Londoni, C; Manta, R; Portincasa, P; Ridola, L; Sacco, R; Scaccianoce, G; Tanzilli, A; Vassallo, R; Zullo, A | 1 |
Göktaş, Z; Kahramanoğlu Aksoy, E; Nazlıgül, Y; Pirinçci Sapmaz, F; Uzman, M | 1 |
Morgando, A; Younes, R | 1 |
Choe, JW; Hyun, JJ; Jung, SW; Jung, YK; Kim, SY; Koo, JS; Lee, SW; Yim, HJ | 1 |
Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G | 1 |
Allegretta, L; Baldassarre, G; Brandimarte, G; Cassieri, C; De Bastiani, R; Di Mario, F; Elisei, W; Ferronato, A; Franceschi, M; Licci, C; Miraglia, C; Penna, A; Picchio, M; Pranzo, G; Rizzo, GL; Savarino, E; Scida, S; Tursi, A | 1 |
Chen, Q; Liang, X; Liu, W; Long, X; Lu, H; Yu, L | 1 |
Baghbanian, M; Mirvakili, M; Salmanroghani, H; Salmanroghani, R; Sanati, G; Yazdian, P | 1 |
Robotis, J; Rokkas, T; Tsiodras, S | 1 |
Chen, CL; Hsu, PI; Kao, JY; Kao, SS; Pan, CY; Peng, NJ; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC | 1 |
Bazzoli, F; Conigliaro, R; Eusebi, LH; Farinati, F; Grande, G; Gravina, AG; Ierardi, E; Maconi, G; Panarese, A; Romano, M; Romiti, A; Savarino, E; Stasi, E; Zagari, RM | 1 |
Dore, MP; Graham, DY; Lu, H | 1 |
Cai, T; Tang, D; Wang, F; Yao, Y; Yuan, L; Yue, C | 1 |
Heo, JJ; Jung, K; Kim, JH; Kim, SE; Moon, W; Park, MI; Park, SJ; Roh, JH | 1 |
Andreev, DN; Dicheva, DT; Maiev, IV; Partzvania-Vinogradova, EV; Yurenev, GL | 1 |
Kim, JM; Kim, N; Lee, DH; Lee, JW; Lee, SM; Nam, RH; Soo In, C | 1 |
Gisbert, JP; McNicholl, AG; Nyssen, OP | 1 |
Fallone, CA; Malfertheiner, P; Moss, SF | 1 |
Chen, Q; Chen, Y; Gao, H; Graham, DY; Ji, Y; Li, D; Liang, X; Liu, M; Liu, W; Long, X; Lu, H; Song, Y; Sun, Y; Xu, B; Xu, G; Yu, L; Zhang, W; Zhao, Y | 1 |
Bignon, E; Blin, P; Diquet, B; Droz-Perroteau, C; Guiard, E; Lassalle, R; Lelievre, B; Mégraud, F; Moore, N; Rouyer, M; Tison, F; Zerbib, F | 1 |
Acosta-Gonzales, G; Alsamman, MA; Moss, SF; Resnick, MB; Shawwa, K; Vecchio, EC | 1 |
de Andrés, E; Gómez Hernando, C; Gómez Rodríguez, R; Muñoz Gómez, P; Sierra Bernal, C; Valle Muñoz, J | 1 |
Jin, Z; Li, Y; Lin, D; Lin, L; Meng, F; Pan, J; Shi, Z; Wu, J; Yang, N; Zhang, J; Zhou, Q | 1 |
Huang, Y; Jiang, Y; Tang, Z; Wang, Y; Yan, W; Ye, Z; Zhang, Y; Zhou, Y | 1 |
Graham, DY; Huang, Y; Ji, Y; Liang, X; Lu, H; Luo, L; Yu, L | 1 |
Kim, N; Lee, DH; Lee, JW; Park, YS; Shin, CM; Yoon, H; Yoon, K | 1 |
Cogdill, AG; Guevara, B | 1 |
Alcaide, N; Areia, M; Ariño, I; Axon, T; Barrio, J; Bordin, D; Boyanova, L; Brglez Jurecic, N; Bujanda, L; Buzas, G; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernández, M; Dominguez-Cajal, M; Garre, A; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Kunovský, L; Kupcinskas, L; Lamy, V; Leja, M; Lerang, F; Lucendo, A; Marcos Pinto, R; María Botargues Bote, J; Mégraud, F; Milosavljevic, T; Modolell, I; Niv, Y; Nyssen, OP; O'Morain, C; Ortuño, J; Pérez Lasala, J; Pérez-Aisa, Á; Perona, M; Phull, P; Przytulski, K; Rodrigo-Sáez, L; Rokkas, T; Romero, PM; Shvets, O; Simsek, I; Tepes, B; Tonkic, A; Venerito, M; Voynovan, I | 1 |
Antonelli, G; Borghi, C; Cavallo, R; Fiorini, G; Lazzarotto, T; Pavoni, M; Saccomanno, L; Saracino, IM; Vaira, D; Zullo, A | 1 |
Huang, Y; Lu, J; Lu, X; Miao, S; Sun, H; Wang, Y; Wu, J; Ye, Z; Zhou, Y | 1 |
Alcaide, N; Barrio, J; Bujanda, L; Burgos, D; Caldas, M; Calvet, X; Castro, M; de la Coba, C; Di Maira, T; Dominguez-Cajal, M; Fernandez, N; Fernández-Salazar, L; Ferrer, L; Figuerola, A; Garre, A; Gisbert, JP; Gomez Rodriguez, BJ; Gomez, B; Gomez-Camarero, J; Hinojosa, J; Huguet, JM; Jimenez-Moreno, M; Lucendo, A; Mata Romero, P; Megraud, F; Modollel, I; Molina-Infante, J; Nyssen, OP; O'Morain, C; Ortuño, J; Perez-Aisa, A; Perona, M; Pozzati, L; Puig, I; Resina, E; Rodrigo, L; Tito, L; Varela, P | 1 |
Calvo, PL; Cisarò, F; Pizzol, A | 1 |
Abbas, Z; Asim, M; Baqai, K; Laique, N; Samejo, SA | 1 |
Hu, JN; Ji, CR; Ji, R; Li, LX; Li, YQ; Li, YY; Lin, MJ; Liu, J; Qiao, C; Qu, JY; Zuo, XL | 1 |
Chang, YL; Hsu, PI; Kim, SE; Liou, WS; Shiu, SI; Tu, YK; Tung, YC; Wu, MF; Yang, JC; Yeh, HZ | 1 |
Arslan, M; Balamtekin, N; Günal, A | 1 |
Cho, SJ; Choi, J; Chung, H; Chung, SJ; Kim, JL; Kim, SG; Lee, A | 1 |
Brglez Jurecic, N; Espada Sanchez, M; Gisbert, J; Mégraud, F; O'Morain, C; Perez Nyssen, O; Tepes, B; Tepes, K | 1 |
Ahn, JY; Choi, KD; Gong, EJ; Jung, HY; Jung, KW; Kim, DH; Lee, GH; Lee, JH; Na, HK; Pih, GY; Song, HJ | 1 |
Areia, M; Castro-Fernandez, M; Fernanadez-Salazar, L; Fernandez-Bermejo, M; Gasbarrini, A; Gisbert, JP; Gomez-Rodriguez, BJ; Gravina, AG; Huguet, JM; Malfertheiner, P; Megraud, F; Nuñez, O; Nyssen, OP; O'Morain, C; Ortuñ, J; Pellicano, R; Perez-Aisa, A; Perona, M; Pinto, RM; Pozzati, L; Puig, I; Rodrigo, L; Romano, M; Vaira, D; Venerito, M | 1 |
Coşkun Sökmen, F; Demirci, S; Kasapoğlu, B; Yozgat, A | 1 |
Barcenilla Laguna, J; Bonoso Criado, R; Cabezudo Molleda, L; García Castro, MA; González de Castro, E; Maestro Antolín, S; Montero Moretón, Á; Moreira Da Silva, BA; Pérez Citores, L; Pérez Millán, AG; Santos Santamarta, F | 1 |
Graham, DY; Howden, CW | 1 |
Han, MH; Hwang, JY; Jeon, SW; Kim, C; Kwon, YH; Lee, JE; Nam, SY; Park, JH; Seo, AN | 1 |
Alsamman, MA; Argueta, EA; D'Agata, EMC; Moss, SF | 1 |
Jeon, JY; Kim, B; Kim, MG; Kim, SY; Lee, J; Moon, SJ; Oh, K; Song, GS | 1 |
Choi, IJ; Kim, CG; Kim, YI; Lee, JY; Park, B; Park, JY | 1 |
De Francesco, V; Fiorini, G; Gatta, L; Manta, R; Saracino, IM; Vaira, D; Zullo, A | 1 |
Lee, YC; Liou, JM; Wu, MS | 1 |
Argüelles Arias, F; Castro Laria, L; Caunedo Álvarez, Á; Fernández Álvarez, P; Gómez Rodríguez, BJ; Moreno Márquez, C; Valdés Delgado, T | 1 |
Bontems, P; Cadranel, S; Kotilea, K; Mahler, T; Miendje Deyi, VY; Nguyen, J; Salame, A; Verset, L | 1 |
Ang, D; Ang, TL; Lim, KW; Tan, M; Wong, YJ; Yih Wong, AS | 1 |
Alcedo, J; Amador, J; Bujanda, L; Calvet, X; Castro-Fernández, M; Fernández-Salazar, L; Gené, E; Gisbert, JP; Lanas, Á; Lucendo, AJ; Molina-Infante, J; Nyssen, OP; Pérez-Aisa, A; Puig, I | 1 |
Cho, JH; Jin, SY; Park, S | 1 |
Dutta, AK; Phull, PS | 1 |
Baik, GH; Bang, CS; Jang, HJ; Kae, SH; Kim, HY; Kim, J; Lee, SP; Lim, H; Seo, SI; Shin, WG; Yang, YJ | 1 |
Continisio, A; D'Abramo, FS; Di Leo, A; Ierardi, E; Losurdo, G; Piazzolla, M; Pricci, M; Rima, R | 1 |
Antonowicz, S; Dabrowski, A; Daniluk, J; Gugnacki, P; Krzyzak, M; Maslach, D; Mlynarczyk, M; Rogalski, P; Swidnicka-Siergiejko, A; Wasielica-Berger, J | 1 |
Abbondio, M; Bibbò, S; Dore, MP; Loria, M; Niolu, C; Pes, GM; Sau, R; Tanca, A; Uzzau, S | 1 |
Breslin, CB; Fenelon, O; Glennon, L; Yu, T | 1 |
Almeida, N; Bastos, I; Branquinho, D; Calhau, C; Correia, C; Fernandes, A; Figueiredo, P; Gravito-Soares, E; Leal, C; Vasconcelos, H | 1 |
Li, T; Zhou, Y | 1 |
Li, CL; Lu, HP; Ren, XL; Song, ZQ; Suo, BJ; Tian, XL; Yao, XY; Zhang, H; Zhang, YX; Zhou, LY | 1 |
Bair, MJ; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; El-Omar, EM; Fang, YJ; Hsu, YC; Hu, WH; Jiang, XT; Kuo, CC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Wu, MS; Yang, TH; Yu, CC | 1 |
Niu, Z; Ren, X; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
Chehter, EZ; de Moraes Andrade, PV; Monteiro, YM | 1 |
Li, C; Lu, H; Ren, X; Song, Z; Suo, B; Tian, X; Yao, X; Zhang, H; Zhang, Y; Zhou, L | 2 |
Boal Carvalho, P; Cotter, J; Freitas, M; Lima Capela, T; Macedo Silva, V; Magalhães, J | 1 |
Chen, J; Chen, X; Ding, Z; Han, Y; Huang, Y; Liang, X; Lu, H; Xu, F; Zeng, X | 1 |
Chen, J; Ding, Z; Guo, Y; Han, Y; Huang, Y; Liang, X; Lu, H; Wang, J; Xu, P | 1 |
Chouhan, MI; Hallur, VK; Kumar, C; Makashir, MS; Nayak, HK; Padhy, BM; Panigrahi, MK; Samal, SC; Sethi, S | 1 |
Kim, JH; Lee, SY; Park, HS; Sung, IK | 1 |
Ang, TL; Aye, TT; Basir, DN; Lee, YY; Luu, MN; Mahachai, V; Miftahussurur, M; Quach, DT; Sollano, JD; Vannarath, S; Vilaichone, RK; Vutha, K | 1 |
Huang, L; Li, A; Li, K; Lin, K; Wang, Y; Yang, S; Ye, Y | 1 |
71 review(s) available for bismuth and metronidazole
Article | Year |
---|---|
[Should Helicobacter infection be treated?].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 1991 |
Campylobacter pylori--therapy review.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Campylobacter Infections; Drug Therapy, Combination; Humans; Metronidazole; Organometallic Compounds; Salicylates; Salicylic Acid | 1989 |
The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Randomized Controlled Trials as Topic; Tetracycline | 1995 |
Treating peptic ulcer: an ongoing challenge.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline | 1995 |
Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tinidazole | 1994 |
[Management of the peptic ulcer patient in the Helicobacter pylori age].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Breath Tests; Child; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Immunologic Techniques; Lymphoma, Non-Hodgkin; Metronidazole; Peptic Ulcer; Stomach Neoplasms | 1994 |
Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; United States | 1994 |
Endoscopic and histologic resolution of gastric pseudolymphoma (reactive lymphoid hyperplasia) following treatment with bismuth and oral antibiotics.
Topics: Aged; Amoxicillin; Biopsy; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Metronidazole; Organometallic Compounds; Ranitidine; Salicylates; Stomach; Stomach Neoplasms | 1994 |
Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; United States | 1994 |
[Treatment of Helicobacter pylori infection in adults].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Metronidazole; Peptic Ulcer; Recurrence; Treatment Outcome | 1994 |
[Treatment of Helicobacter pylori infection in children].
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Metronidazole; Recurrence; Treatment Outcome | 1994 |
Duodenal ulcer treatment: progress from pH to HP.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Metronidazole; Tetracycline | 1994 |
[Alternatives of drug therapy in Helicobacter pylori infections].
Topics: Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Oxytetracycline | 1994 |
Helicobacter pylori infection.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Stomach Neoplasms; Stomach Ulcer; Tetracycline | 1993 |
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Contraindications; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Misoprostol; Peptic Ulcer; Predictive Value of Tests; Proton Pump Inhibitors; Recurrence | 1996 |
Triple therapy and Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Stomach Neoplasms; Stomach Ulcer; Tetracycline; Time Factors | 1996 |
Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Hospitals, University; Humans; Metronidazole; Norway; Oxytetracycline; Peptic Ulcer; Stomach Diseases; Urea; Urease | 1996 |
Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Tetracyclines; Tinidazole | 1996 |
[Helicobacter pylori eradication: triple therapy versus dual therapy].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline; Tinidazole; Treatment Outcome | 1996 |
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Monte Carlo Method; Organometallic Compounds; Patient Compliance; Proton Pump Inhibitors; Recurrence; Salicylates; Tetracycline; Treatment Outcome | 1997 |
Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Salicylates; Tetracycline | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Metronidazole; Omeprazole; Penicillins; Proton Pump Inhibitors | 1997 |
Treatment strategies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Protein Synthesis Inhibitors; Salicylates; Tetracycline | 1997 |
Review: Helicobacter pylori. Current issues and new directions.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Peptic Ulcer; Stomach Neoplasms | 1997 |
Peptic ulcer disease in the 1990s: an Asian perspective.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Asia; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer | 1997 |
Treatment of Helicobacter pylori infection: a review of the world literature.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Smoking; Tetracycline; Treatment Outcome | 1996 |
[Treatment of Helicobacter pylori infections].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Penicillins; Tetracycline; Time Factors | 1998 |
Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline; Treatment Outcome | 1999 |
Pharmacotherapy for inducing and maintaining remission in pouchitis.
Topics: Adult; Bismuth; Butyrates; Enema; Humans; Metronidazole; Postoperative Complications; Pouchitis; Remission Induction; Suppositories | 2000 |
Treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2001 |
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; MEDLINE; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer Hemorrhage; Randomized Controlled Trials as Topic; Ranitidine; Recurrence; Risk Factors; Salicylates; Sensitivity and Specificity | 2001 |
A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracyclines | 2001 |
[Classic triple therapy for Helicobacter pylori infection].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Salicylates; Tetracycline | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Histamine H2 Antagonists; Humans; Metronidazole; Patient Care Planning; Penicillins; Proton Pumps; Ranitidine; Recurrence | 2002 |
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Ditiocarb; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2003 |
Is it time for quadruple therapy to be first line?
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Ranitidine | 2003 |
Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2004 |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.
Topics: Antacids; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Guideline Adherence; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Tetracycline; Treatment Outcome | 2004 |
[Anti-Helicobacter pylori quadruple therapy].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2005 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2006 |
Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline | 2008 |
Helicobacter pylori: diagnosis and treatment.
Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Ofloxacin; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Treatment Failure | 2009 |
Pylera for the eradication of Helicobacter pylori infection.
Topics: Administration, Oral; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Randomized Controlled Trials as Topic; Tetracycline; Treatment Outcome | 2009 |
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Outcome Assessment, Health Care; Patient Compliance; Practice Guidelines as Topic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline | 2010 |
Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Ranitidine; Tetracycline; Treatment Failure; Treatment Outcome | 2010 |
Diagnosis and treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Denmark; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Stomach Neoplasms; Tetracycline | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Tetracycline | 2011 |
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Treatment Failure | 2013 |
Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2013 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors | 2014 |
Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms | 2014 |
Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Humans; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2015 |
Helicobacter pylori therapy: a paradigm shift.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Standard of Care; Treatment Outcome | 2016 |
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2016 |
Novel and Effective Therapeutic Regimens for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Mutation; Prevalence; Probiotics; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides; Tetracycline; Tetracycline Resistance | 2017 |
Helicobacter pylori management in ASEAN: The Bangkok consensus report.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Consensus; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; Proton Pump Inhibitors; Taiwan; Tetracycline; Thailand; Treatment Outcome; United States | 2018 |
Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2018 |
Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2019 |
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Canada; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Tetracycline; United States | 2019 |
Recent progress in Helicobacter pylori treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Probiotics; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Vitamins | 2020 |
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Biopsy; Bismuth; Breath Tests; Clarithromycin; Culture Techniques; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Feces; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Nitro Compounds; Organometallic Compounds; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors; Rifabutin; Salicylates; Salvage Therapy; Serologic Tests; Stomach Neoplasms; Tetracycline; Thiazoles; Treatment Outcome; Urea | 2020 |
Efficacy of second-line regimens for
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Network Meta-Analysis; Outcome Assessment, Health Care; Practice Guidelines as Topic; Proton Pump Inhibitors; Quinolones; Randomized Controlled Trials as Topic; Tetracycline | 2020 |
Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Rifabutin; Tetracycline; Treatment Failure | 2021 |
Treatment of Refractory
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors | 2022 |
V Spanish Consensus Conference on Helicobacter pylori infection treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors | 2022 |
Treatment of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Hypersensitivity; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Penicillins; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2021 |
Third-line and rescue therapy for refractory
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Rifabutin; Tetracycline | 2023 |
Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2023 |
187 trial(s) available for bismuth and metronidazole
Article | Year |
---|---|
Eradicating Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter pylori; Humans; Metronidazole; Time Factors | 1992 |
Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Single-Blind Method; Tetracycline | 1992 |
Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Prospective Studies; Recurrence; Risk Factors; Sucralfate; Tetracycline | 1992 |
Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Bismuth; Duodenal Ulcer; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Longitudinal Studies; Male; Metronidazole; Middle Aged; Ranitidine; Recurrence; Regression Analysis; Water | 1992 |
Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Bismuth; Circadian Rhythm; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Erythromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Stomach Ulcer | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Ranitidine; Recurrence; Risk Factors; Salicylates; Stomach Ulcer; Tetracycline | 1992 |
Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy.
Topics: Adult; Aged; Antacids; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Tetracycline | 1992 |
Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies | 1991 |
The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Salicylates | 1991 |
Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Ranitidine; Salicylates; Single-Blind Method; Tetracycline | 1991 |
Third molar surgery: the effect of primary closure, wound dressing and metronidazole on postoperative recovery.
Topics: Acetaminophen; Adult; Analgesics; Bandages; Bismuth; Caffeine; Codeine; Drug Combinations; Female; Humans; Hydrocarbons, Iodinated; Male; Metronidazole; Molar, Third; Pain, Postoperative; Surgical Wound Infection; Suture Techniques; Sutures; Tooth, Impacted; Wound Healing | 1991 |
Chronic alcoholic gastritis. Roles of alcohol and Helicobacter pylori.
Topics: Adult; Alcoholism; Aluminum Hydroxide; Amoxicillin; Bismuth; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Salicylates; Temperance | 1991 |
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline; Treatment Outcome | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Recurrence | 1995 |
[Antibacterial treatment of gastric ulcers associated with Helicobacter pylori without acid suppression].
Topics: Aluminum Hydroxide; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Magnesium Hydroxide; Metronidazole; Omeprazole; Simethicone; Stomach Ulcer; Tetracycline | 1995 |
Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up.
Topics: Adult; Aged; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Spiramycin; Treatment Outcome | 1995 |
Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients.
Topics: Adult; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Salicylates; Time Factors | 1995 |
Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Recurrence; Tetracycline; Time Factors | 1995 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Metronidazole; Nitrates; Omeprazole; Prospective Studies; Ranitidine; Recurrence; Tetracycline; Time Factors; Tinidazole | 1995 |
Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers.
Topics: Adult; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Sucralfate; Tetracycline | 1995 |
Association of symptoms with Helicobacter pylori infection in children.
Topics: Adolescent; Biopsy; Bismuth; Child; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Duodenum; Female; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Prospective Studies | 1995 |
A 1-h topical therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Male; Metronidazole; Middle Aged; Pronase; Time Factors; Treatment Outcome | 1995 |
Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Antacids; Bismuth; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Prospective Studies; Quality of Life; Recurrence; Severity of Illness Index; Time Factors | 1994 |
Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients.
Topics: Antacids; Biopsy; Bismuth; DNA; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Female; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Male; Metronidazole; Middle Aged; Omeprazole; Oxytetracycline; Stomach | 1994 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Recurrence | 1994 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Leukocytes; Male; Metronidazole; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pumps; Recurrence | 1994 |
Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Tetracycline; Time Factors | 1994 |
Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Time Factors | 1994 |
Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease.
Topics: Adult; Aged; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Recurrence | 1994 |
[The effect of the eradication of H. pylori on the intractable ulcer].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Recurrence | 1993 |
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline | 1993 |
Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Salicylates; Tetracycline | 1993 |
Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Cisapride; Double-Blind Method; Duodenum; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Piperidines; Pyloric Antrum | 1993 |
Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Stomach Ulcer; Tetracycline | 1993 |
Patient factors affecting Helicobacter pylori eradication with triple therapy.
Topics: Adult; Age Factors; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Marriage; Metronidazole; Middle Aged; Multivariate Analysis; Patient Compliance; Prospective Studies; Recurrence; Stomach Ulcer; Tetracycline | 1993 |
Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Palliative Care; Peptic Ulcer; Ranitidine; Treatment Outcome | 1996 |
Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Chile; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Recurrence; Salicylates; Single-Blind Method; Time Factors | 1996 |
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Prospective Studies; Tetracycline | 1995 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Premedication; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Time Factors | 1996 |
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Tetracycline | 1995 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Recurrence; Serologic Tests; Tetracycline | 1996 |
One-week therapy for Helicobacter pylori. A randomized trial of two treatment regimens.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Salicylates | 1996 |
Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Malaysia; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Recurrence; Time Factors | 1996 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Tetracycline | 1997 |
Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Topics: Activities of Daily Living; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Hospitalization; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer Hemorrhage; Stomach Ulcer; Tetracycline | 1997 |
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Oxytetracycline; Penicillins; Prospective Studies; Recurrence; Time Factors | 1997 |
One week treatment for Helicobacter pylori infection.
Topics: Adolescent; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Breath Tests; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Metronidazole; Organometallic Compounds | 1997 |
Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Nizatidine; Omeprazole; Organometallic Compounds; Penicillins; Ranitidine; Salicylates | 1997 |
Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Tetracycline; Time Factors | 1997 |
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Treatment Outcome | 1997 |
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Pyloric Antrum; Ranitidine | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Dyspepsia; Evaluation Studies as Topic; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Medical Records; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Taste Disorders | 1997 |
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Administration Schedule; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Naproxen; Organometallic Compounds; Prospective Studies; Stomach Ulcer; Tetracycline | 1997 |
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Smoking; Tetracycline; Tetracyclines | 1997 |
Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Combinations; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Salicylates; Tetracycline; Urea | 1997 |
Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peru; Recurrence; Salicylates; Tetracycline; Tinidazole | 1997 |
[Hormonal changes and secretion and stomach mucosal microstructure in the course of H. pylori in patients with duodenal ulcer].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Somatostatin | 1997 |
[Endocrine and exocrine gastric mucosal secretion in the course of H. pylori eradication in patients with non-ulcer dyspepsia].
Topics: Amoxicillin; Bismuth; Dyspepsia; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Somatostatin; Stomach Ulcer | 1997 |
Sucralfate as an alternative to bismuth in quadruple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Sucralfate; Tetracycline | 1997 |
One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer Hemorrhage; Ranitidine; Recurrence; Tetracycline | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Placebos; Proton Pump Inhibitors; Ranitidine; Tetracycline | 1998 |
Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 1998 |
Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Treatment Outcome | 1998 |
Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Stomach Ulcer; Tetracycline; Treatment Outcome | 1998 |
Helicobacter pylori eradication: kill the bug and save the pill?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Naproxen; Peptic Ulcer; Prospective Studies; Risk Factors; Single-Blind Method; Tetracycline | 1998 |
Randomized comparison of 1-hour topical method vs. amoxycillin plus omeprazole for eradication of Helicobacter pylori in duodenal ulcer patients.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clinical Protocols; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter pylori; Humans; Intubation, Gastrointestinal; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Pronase; Ranitidine | 1998 |
One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Ranitidine; Time Factors; Treatment Failure | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Tetracycline; Treatment Outcome | 1998 |
Continuous and more effective duodenal ulcer healing under therapy with bismuth and two antibiotics than with dual therapy comprising omeprazole and amoxicillin.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Female; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Tetracycline; Treatment Outcome | 1998 |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 1998 |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome; Urea | 1999 |
One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Tetracycline | 1999 |
[The treatment of chronic duodenal ulcer with accompanying Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clinical Protocols; Duodenal Ulcer; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Retrospective Studies; Treatment Outcome | 1998 |
The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Penicillins; Ranitidine; Stomach Ulcer | 1999 |
Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Patient Compliance; Ranitidine; Tetracycline; Urea | 1999 |
Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori.
Topics: Adult; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Ranitidine; Time Factors | 1999 |
Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 1999 |
Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Prospective Studies; Ranitidine; Spiramycin | 1999 |
Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments.
Topics: Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 1999 |
Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; China; Colloids; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pectins | 1999 |
Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Double-Blind Method; Drug Therapy, Combination; Female; Ferrous Compounds; Helicobacter Infections; Helicobacter pylori; Hemoglobins; Humans; Intestinal Absorption; Male; Metronidazole; Nutritional Status; Organometallic Compounds; Placebos; Pyloric Antrum | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Ranitidine; Treatment Outcome | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Salicylates; Treatment Outcome | 1999 |
Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline; Treatment Outcome | 1999 |
One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Combinations; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Penicillins; Peptic Ulcer; Prospective Studies; Ranitidine; Treatment Outcome | 1999 |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 1999 |
A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Maintenance Organizations; Helicobacter Infections; Helicobacter pylori; Humans; Male; Massachusetts; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Program Evaluation; Salicylates; Tetracycline; Treatment Outcome | 1999 |
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication].
Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Recurrence; Wound Healing | 1999 |
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Enzyme Inhibitors; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Tetracycline | 2000 |
Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Outlet Obstruction; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; Treatment Outcome | 2000 |
Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Esophagitis, Peptic; Female; Follow-Up Studies; Gastroesophageal Reflux; Gastroscopy; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Treatment Failure | 2000 |
Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Female; Follow-Up Studies; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline; Treatment Outcome | 2000 |
Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Patient Compliance; Prospective Studies; Salicylates; Tetracycline; Treatment Outcome | 2000 |
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome | 2000 |
Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage--a long-term randomized, controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Male; Metronidazole; Middle Aged; Peptic Ulcer Hemorrhage; Prognosis; Secondary Prevention | 2000 |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Hong Kong; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prevalence; Ranitidine; Treatment Outcome; Urea | 2001 |
Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline; Treatment Outcome; Urea | 2001 |
Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Calcium Carbonate; Drug Therapy, Combination; Epithelium; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Male; Metronidazole; Middle Aged; Organometallic Compounds; Penicillins; Placebos; Risk Factors; Salicylates; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2001 |
Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Safety | 2001 |
High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine | 2001 |
Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Ranitidine; Treatment Outcome; Urea; Urease | 2001 |
Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer Perforation; Prospective Studies; Ranitidine; Recurrence; Retrospective Studies; Tetracycline | 2001 |
Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy, Needle; Bismuth; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Esophagoscopy; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine; Urea | 2001 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 2001 |
Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome | 2001 |
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Penicillins; Peptic Ulcer; Ranitidine; Retrospective Studies | 2001 |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Omeprazole; Tetracycline; Treatment Failure | 2002 |
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Proton Pumps; Treatment Failure; Treatment Outcome | 2002 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pantoprazole; Peptic Ulcer; Prospective Studies; Sulfoxides; Tetracycline; Treatment Failure; Treatment Outcome | 2002 |
The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine; Treatment Outcome | 2002 |
One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Treatment Outcome | 2002 |
Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Ranitidine; Tetracycline | 2002 |
Patients with endoscopic gastritis and/or duodenitis improve markedly following eradication of Helicobacter pylori, although less so than patients with ulcers.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenitis; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Ranitidine; Spiramycin; Time Factors | 2002 |
Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline; Treatment Outcome | 2003 |
Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment.
Topics: Adult; Amoxicillin; Antacids; Bismuth; Calcium Carbonate; Drug Therapy, Combination; Dyspepsia; Female; Gastric Acidity Determination; Gastritis, Atrophic; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Retrospective Studies; Risk Factors; Salicylates; Tetracycline | 2003 |
Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Gastric Mucosa; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Salvage Therapy; Tetracyclines; Urea | 2003 |
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Tetracycline; Urea | 2003 |
Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides; Tetracycline | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Severity of Illness Index; Treatment Outcome | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Pantoprazole; Prospective Studies; Ranitidine; Sulfoxides; Tinidazole; Treatment Failure; Urea | 2003 |
Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Oxytetracycline; Specimen Handling; Treatment Outcome | 2004 |
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Pilot Projects; Prospective Studies; Proton-Translocating ATPases; Rabeprazole; Salicylates; Tetracycline; Treatment Outcome | 2004 |
Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Drug Resistance, Bacterial; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Ranitidine; Tetracycline; Treatment Failure; Treatment Outcome | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pilot Projects; Ranitidine; Tetracycline; Treatment Outcome | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Tetracycline | 2004 |
Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Chi-Square Distribution; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Tetracycline; Treatment Outcome; Turkey | 2005 |
7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 2005 |
Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication.
Topics: Administration, Oral; Adolescent; Adult; Antacids; Anti-Bacterial Agents; Biological Availability; Bismuth; Cross-Over Studies; Drug Combinations; Food-Drug Interactions; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tetracycline | 2005 |
Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Minocycline; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Ranitidine; Tetracycline; Treatment Outcome; Urease; Young Adult | 2006 |
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Contraindications; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pantoprazole; Pyloric Antrum; Stomach Ulcer; Tetracycline; Treatment Failure | 2006 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; Double-Blind Method; Dyspepsia; Gastric Emptying; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Metronidazole; Omeprazole; Peptic Ulcer; Sucrose; Tetracycline; Treatment Outcome | 2006 |
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Middle Aged; Single-Blind Method; Statistics, Nonparametric; Tetracycline; Treatment Outcome | 2007 |
Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Cross-Over Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Ranitidine; Urea | 2008 |
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Tetracycline; Treatment Outcome; Young Adult | 2009 |
The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Ascorbic Acid; Bismuth; Dietary Supplements; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Young Adult | 2009 |
A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; China; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Pilot Projects; Placebos; Rural Population; Tetracycline; Urea | 2010 |
Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Republic of Korea; Tetracycline; Time Factors; Treatment Outcome | 2010 |
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Case-Control Studies; Chi-Square Distribution; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Statistics, Nonparametric; Surveys and Questionnaires; Tetracycline; Treatment Outcome | 2010 |
Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Medication Adherence; Metronidazole; Middle Aged; Pantoprazole; Prospective Studies; Tetracycline; Time Factors; Treatment Outcome; Urea | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histocytochemistry; Humans; Italy; Male; Metronidazole; Middle Aged; Pantoprazole; Prospective Studies; Tetracycline; Time Factors; Treatment Outcome; Urea; Young Adult | 2011 |
Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Salicylates; Tetracycline; Young Adult | 2012 |
Lycopene an adjunctive therapy for Helicobacter pylori eradication: a quasi-control trial.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Bismuth; Carotenoids; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lycopene; Male; Metronidazole; Middle Aged; Omeprazole; Treatment Outcome | 2012 |
Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Treatment Outcome; Urea; Young Adult | 2013 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Latin America; Male; Medication Adherence; Metronidazole; Middle Aged; Primary Prevention; Recurrence; Risk; Stomach Neoplasms; Young Adult | 2013 |
Pharmacokinetics of metronidazole, tetracycline and bismuth in healthy volunteers after oral administration of compound tablets containing a combination of metronidazole, tetracycline hydrochloride and bismuth oxide.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Biological Availability; Bismuth; Drug Combinations; Fasting; Female; Healthy Volunteers; Humans; Male; Metronidazole; Tablets; Tetracycline; Young Adult | 2015 |
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Turkey | 2014 |
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rabeprazole; Tetracycline | 2015 |
Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Cytochrome P-450 CYP2C19; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tertiary Care Centers; Treatment Outcome; Young Adult | 2016 |
Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Bismuth; Breath Tests; Clinical Protocols; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Salicylates; Turkey | 2015 |
Phytomedicine-based and Quadruple Therapies in Helicobacter pylori Infection: A Comparative, Randomized Trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Phytotherapy; Plant Extracts; Treatment Outcome; Young Adult | 2015 |
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Young Adult | 2015 |
Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Potassium Citrate; Prospective Studies; Rabeprazole; Tetracycline; Time Factors; Young Adult | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Tetracycline; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors | 2017 |
Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Tetracycline; Young Adult | 2017 |
Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Republic of Korea | 2018 |
New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; China; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Tetracycline; Young Adult | 2018 |
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2018 |
Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Tetracycline | 2018 |
The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Metronidazole; Middle Aged; Probiotics; Proton Pump Inhibitors; Retrospective Studies; Tetracycline | 2018 |
Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Peptic Ulcer; Prospective Studies; Treatment Outcome | 2018 |
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2019 |
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
Addition of bismuth to standard triple therapy for Helicobacter pylori eradication: a randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 2020 |
Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Treatment Outcome | 2020 |
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Republic of Korea; RNA, Ribosomal, 23S; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2020 |
Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Republic of Korea | 2021 |
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
Topics: Abdominal Pain; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Metronidazole; Probiotics; Treatment Outcome | 2022 |
Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Prospective Studies; Treatment Outcome | 2021 |
Comparison of tailored
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Republic of Korea; Treatment Outcome | 2022 |
Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome | 2022 |
Metagenomic Changes of Gut Microbiota following Treatment of
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Limosilactobacillus reuteri; Metronidazole; Proton Pump Inhibitors; Rabeprazole; RNA, Ribosomal, 16S; Tetracycline; Treatment Outcome | 2022 |
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline | 2023 |
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Australia; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; RNA, Ribosomal, 16S; Young Adult | 2023 |
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Quinolones; Treatment Outcome | 2023 |
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cefuroxime; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Hypersensitivity; Medication Adherence; Metronidazole; Minocycline; Penicillins; Tetracycline; Treatment Outcome | 2023 |
A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2023 |
Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Potassium Citrate; Tetracycline | 2023 |
Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Minocycline; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2023 |
Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2023 |
Comparison of the efficacies of triple, quadruple and sequential antibiotic therapy in eradicating Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 2023 |
187 other study(ies) available for bismuth and metronidazole
Article | Year |
---|---|
Eradicating Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 1992 |
Eradicating Helicobacter pylori.
Topics: Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 1992 |
Clinicopathological assessment of gastric biopsy samples of patients with Helicobacter pylori infection--metronidazole resistance and compliance problems in the United Arab Emirates.
Topics: Adolescent; Adult; Antacids; Bacteriological Techniques; Bismuth; Doxycycline; Drug Resistance, Microbial; Dyspepsia; Female; Follow-Up Studies; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Prevalence; Prospective Studies; Stomach; Tinidazole; United Arab Emirates | 1992 |
Eradication of Helicobacter pylori reduces gastric and duodenal ulcer recurrence.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Ranitidine; Recurrence; Salicylates; Tetracycline | 1992 |
[Treatment of stomach ulcer with bismuth subnitrate, oxytetracycline and metronidazole].
Topics: Adult; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Recurrence; Stomach Ulcer | 1992 |
Short report: short-term triple therapy for H. pylori-associated duodenal ulcer disease.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Tetracycline | 1992 |
[Helicobacter pylori: from harmless commensal to clinically significant disease factor].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Recurrence; Stomach Ulcer; Tetracycline | 1992 |
Factors influencing the eradication of Helicobacter pylori with triple therapy.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Regression Analysis; Salicylates; Stomach Ulcer; Tetracycline | 1992 |
Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Circadian Rhythm; Duodenal Ulcer; Female; Gastric Acid; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Organometallic Compounds; Stomach; Time Factors | 1991 |
Spiral shaped microorganisms in the human duodenal mucosa.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Gram-Negative Bacteria; Humans; Intestinal Mucosa; Male; Metronidazole; Organometallic Compounds | 1991 |
Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Campylobacter Infections; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Humans; Metronidazole; Organometallic Compounds | 1990 |
Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection.
Topics: Bismuth; Campylobacter Infections; Drug Therapy, Combination; Duodenal Ulcer; Female; Food; Gastrins; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Tetracycline | 1990 |
Campylobacter pylori in patients with dyspeptic symptoms and endoscopic evidence of erosion(s).
Topics: Adolescent; Adult; Aged; Bismuth; Campylobacter; Duodenitis; Dyspepsia; Endoscopy; Gastric Mucosa; Gastritis; Humans; Metronidazole; Middle Aged; Organometallic Compounds; Pyloric Antrum; Salicylates | 1989 |
[Morphologic change in Campylobacter pylori associated gastritis in and following successful antibacterial therapy].
Topics: Amoxicillin; Bismuth; Campylobacter Infections; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Salicylates | 1989 |
Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.
Topics: Anti-Bacterial Agents; Bismuth; Campylobacter; Cefoxitin; Ciprofloxacin; Erythromycin; Gastritis; Gentamicins; Humans; Metronidazole; Nalidixic Acid; Organometallic Compounds; Penicillin Resistance; Penicillins; Quinolines; Sulfamethoxazole; Tartrates; Trimethoprim | 1985 |
Use of antibiotics to prevent hepatitis and typhlitis in male scid mice spontaneously infected with Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Cecal Diseases; Cecum; Chronic Disease; Helicobacter; Helicobacter Infections; Hepatitis, Animal; Inflammation; Liver; Male; Metronidazole; Mice; Mice, SCID; Neomycin; Rodent Diseases; Tetracycline | 1995 |
[Is measurement of basal levels of serum pepsinogen II useful in proving the eradication of Helicobacter pylori by treatment?].
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pepsinogens; Prospective Studies; Radioimmunoassay; ROC Curve; Sensitivity and Specificity; Stomach; Tetracycline; Time Factors | 1995 |
[The importance of obtaining biopsies of the gastric body in the follow-up after eradicating treatment of Helicobacter pylori].
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Penicillins; Prospective Studies; Pyloric Antrum; Stomach; Tetracycline; Time Factors | 1995 |
[Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine; Salicylates; Tetracycline | 1995 |
Eczema responsive to treatment for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Eczema; Gastroenteritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Recurrence; Salicylates; Tetracycline | 1995 |
Evaluation of antibiotic therapies for eradication of Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Base Sequence; Bismuth; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Helicobacter Infections; Male; Metronidazole; Mice; Mice, Inbred Strains; Molecular Sequence Data; Random Allocation; Stomach Diseases; Tetracycline | 1995 |
Helicobacter pylori infection in recurrent abdominal pain in childhood: comparison of diagnostic tests and therapy.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Antibodies, Bacterial; Bismuth; Child; Child, Preschool; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Male; Metronidazole; Organometallic Compounds; Polymerase Chain Reaction; Recurrence; Salicylates; Stomach Ulcer | 1995 |
"Cure" of Helicobacter pylori and "cure" of peptic ulcer: do they mean the same thing?
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Recurrence; Tetracycline; Time Factors | 1995 |
Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child.
Topics: Adolescent; Amoxicillin; Bismuth; Chronic Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Remission Induction; Stomach Neoplasms | 1995 |
90% cure: which anti-Helicobacter therapy can achieve this treatment goal?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Tetracycline | 1995 |
Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline | 1995 |
Treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tetracycline | 1995 |
Helicobacter pylori infection and gastric juice vitamin C levels. Impact of eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; Bismuth; Drug Therapy, Combination; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Stomach Neoplasms | 1995 |
Duodenal ulcer healing drugs.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acid; Gastrin-Releasing Peptide; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptides | 1994 |
Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation.
Topics: Adult; Aged; Bismuth; Cell Division; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Longitudinal Studies; Male; Metaplasia; Metronidazole; Middle Aged; Nuclear Proteins; Proliferating Cell Nuclear Antigen; Pyloric Antrum; Tetracycline | 1994 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Ranitidine; Recurrence; Salicylates; Tetracycline; Treatment Failure; Treatment Outcome | 1994 |
[10 days of triple treatment of Helicobacter pylori infection and peptic ulcer. Status after treatment of 4 weeks and of one year].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer; Time Factors | 1994 |
[A Norwegian conference on updating of the treatment of Helicobacter pylori in peptic ulcer. Interessegruppe for Gastroenterologi].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Norway; Omeprazole; Oxytetracycline; Peptic Ulcer | 1994 |
Phospholipase A2 activity in gastric juice from patients with active and H. pylori-eradicated healed duodenal ulcer.
Topics: Adult; Aged; Bile Acids and Salts; Bismuth; Choline; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Juice; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Oxytetracycline; Phospholipases A; Phospholipases A2; Phospholipids | 1994 |
Preservation of gastric antral mucus is associated with failure of eradication of Helicobacter pylori by bismuth, metronidazole and tetracycline.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Administration Schedule; Female; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Neutrophils; Pyloric Antrum; Tetracycline | 1994 |
Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pepsinogens; Peptic Ulcer; Salicylates | 1994 |
Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: a 12-month follow-up study.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Insulin; Male; Metronidazole; Middle Aged; Organometallic Compounds; Pepsinogens; Time Factors | 1994 |
Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Protein-Losing Enteropathies; Salicylates | 1994 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Peptic Ulcer Hemorrhage; Prospective Studies; Ranitidine; Recurrence; Salicylates; Stomach Ulcer | 1994 |
Vitamin C concentration in gastric juice before and after anti-Helicobacter pylori treatment.
Topics: Amoxicillin; Ascorbic Acid; Bismuth; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Organometallic Compounds; Salicylates; Smoking | 1994 |
Omeprazole/amoxicillin versus ranitidine/triple therapy for duodenal ulcer: when is the "same" the same?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Ranitidine; Salicylates; Tetracycline | 1994 |
Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing.
Topics: Adult; Bismuth; Female; Food; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Peptic Ulcer; Protein Precursors; Protein Processing, Post-Translational; Salicylates; Tetracycline | 1993 |
Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis.
Topics: Adult; Biopsy; Bismuth; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Nitrofurantoin; Organometallic Compounds; Pepsinogens; Salicylates | 1993 |
[Helicobacter pylori infection and peptic ulcer].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Tetracycline | 1993 |
[Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease].
Topics: Administration, Oral; Adult; Aged; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Ranitidine; Salicylates; Tetracycline | 1993 |
Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Tetracycline | 1993 |
Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori.
Topics: Acute Disease; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Parietal Cells, Gastric; Tetracycline | 1993 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Metronidazole; Neutrophils; Prospective Studies; Recurrence; Stomach Ulcer | 1993 |
Long-term Helicobacter pylori recurrence after successful eradication with triple therapy.
Topics: Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Recurrence; Salicylates; Tetracycline | 1993 |
Eradication of Helicobacter pylori normalizes serum gastrin concentration and antral gastrin cell number in a patient with primary gastrin cell hyperplasia.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enterochromaffin Cells; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Male; Metronidazole; Middle Aged; Pyloric Antrum; Tetracycline | 1993 |
Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulins; Male; Metronidazole; Middle Aged; Omeprazole; Pyloric Antrum; T-Lymphocytes; Tetracycline | 1993 |
[Eradication of Helicobacter pylori and hemorrhagic recurrence of duodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer Hemorrhage; Tetracycline; Time Factors | 1995 |
Evaluation of a new bismuth-free triple therapy in nude mice and humans.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Colony Count, Microbial; Contraindications; Disease Models, Animal; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Mice; Mice, Inbred BALB C; Mice, Nude; Penicillins; Peptic Ulcer; Recurrence; Severity of Illness Index; Treatment Outcome | 1995 |
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Omeprazole; Patient Compliance; Penicillins; Recurrence; Tetracycline; Time Factors | 1996 |
[What factors influence healing of duodenal ulcer when Helicobacter pylori eradication treatment is used?].
Topics: Adult; Age Factors; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Evaluation Studies as Topic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Multivariate Analysis; Omeprazole; Penicillins; Sex Factors; Smoking; Tetracycline; Time Factors; Wound Healing | 1996 |
Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori.
Topics: Bismuth; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Middle Aged; Omeprazole; Salivary Gland Neoplasms | 1996 |
Helicobacter pylori reinfection after apparent eradication--the Ipswich experience.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Case-Control Studies; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; England; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Recurrence; Stomach Ulcer; Time Factors; Urea | 1996 |
Treatment of Helicobacter pylori infection by topical administration of antimicrobial agents.
Topics: Administration, Topical; Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Intubation, Gastrointestinal; Metronidazole; Penicillins | 1996 |
Evaluation of various oral antimicrobial formulations for eradication of Helicobacter hepaticus.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Base Sequence; Bismuth; Diet; Drinking; Female; Helicobacter; Helicobacter Infections; Male; Metronidazole; Mice; Mice, Inbred A; Mice, Inbred DBA; Molecular Sequence Data; Polymerase Chain Reaction; Rodent Diseases; Tetracycline | 1996 |
[Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori?].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Pyloric Antrum; Stomach; Tetracycline | 1996 |
[Triple-therapy treatment during 1 month versus 2 weeks in gastroduodenal disease due to Helicobacter pylori in children].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Time Factors | 1996 |
Activity of amoxicillin, metronidazole, bismuth salicylate and six aminoglycosides against Helicobacter pylori.
Topics: Aminoglycosides; Amoxicillin; Antacids; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Penicillins; Salicylates; Salicylic Acid | 1996 |
Insulin-like growth factor-I in Helicobacter pylori gastritis and response to eradication using bismuth based triple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Gastric Juice; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Insulin-Like Growth Factor I; Male; Metronidazole; Middle Aged | 1996 |
[Connection between Helicobacter pylori infection and chronic gastrointestinal urticaria].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Bismuth; Chronic Disease; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Penicillins; Urticaria | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Pronase | 1996 |
Six months' experience with a pharmacist-run Helicobacter pylori treatment clinic.
Topics: Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Cost of Illness; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Pilot Projects; Salicylates; Tetracycline | 1996 |
Treating Helicobacter pylori--the best is yet to come?
Topics: Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Tetracycline | 1996 |
A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Tetracycline | 1997 |
Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis.
Topics: Amoxicillin; Bismuth; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged | 1997 |
Triple-drug therapy of Helicobacter pylori infection in duodenal ulcer disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Organometallic Compounds; Recurrence; Tetracycline; Time Factors | 1997 |
Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection.
Topics: Adult; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline | 1997 |
Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment.
Topics: Amoxicillin; Bicarbonates; Bismuth; Carbon Isotopes; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mass Spectrometry; Metronidazole; Middle Aged; Omeprazole; Sensitivity and Specificity; Tetracycline | 1997 |
Identification and eradication of Helicobacter pylori in an isolated patient population.
Topics: Amoxicillin; Bismuth; Cost Savings; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Military Personnel; Organometallic Compounds; Peptic Ulcer; Salicylates; Tetracycline; United States; Utah | 1997 |
Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular?
Topics: Adult; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antitrichomonal Agents; Bismuth; Chaperonin 60; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epithelium; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; HLA-DR Antigens; Humans; Immunohistochemistry; Male; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Tetracycline; Time Factors | 1997 |
Treatment of gastritis in cheetahs (Acinonyx jubatus).
Topics: Acinonyx; Animals; Anti-Bacterial Agents; Antitrichomonal Agents; Biopsy; Bismuth; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Gram-Negative Bacterial Infections; Helicobacter; Helicobacter Infections; Lymphocytes; Male; Metronidazole; Organometallic Compounds; Prospective Studies; Salicylates; Sensitivity and Specificity; Tetracycline; Time Factors | 1997 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline; Tinidazole | 1996 |
Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets.
Topics: Amoxicillin; Animals; Antacids; Bacterial Proteins; Biopsy; Bismuth; DNA, Bacterial; Drug Therapy, Combination; Ferrets; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter; Helicobacter Infections; Metronidazole; Organometallic Compounds; Recurrence; Salicylates; Time Factors; Urease | 1996 |
Characterization and therapy for experimental infection by Helicobacter mustelae in ferrets.
Topics: Amoxicillin; Animals; Antacids; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Female; Ferrets; Gastritis; Helicobacter; Helicobacter Infections; Male; Metronidazole; Organometallic Compounds; Salicylates; Specific Pathogen-Free Organisms | 1996 |
An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Imipenem; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Tetracycline | 1996 |
The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions; Drug Resistance, Microbial; Helicobacter pylori; Histamine H2 Antagonists; Metronidazole; Ranitidine; Streptomycin | 1997 |
Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Oxytetracycline; Peptic Ulcer | 1998 |
The ideal therapy must be defined in each geographical area: experience with a quadruple therapy in Spain.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Spain; Tetracycline | 1998 |
[Polyneuropathy caused by vitamin B12 deficiency secondary to chronic atrophic gastritis and giardiasis].
Topics: Amoxicillin; Anemia, Pernicious; Anti-Bacterial Agents; Antiprotozoal Agents; Bismuth; Duodenitis; Enzyme Inhibitors; Evoked Potentials, Somatosensory; Female; Gastritis, Atrophic; Giardiasis; Helicobacter Infections; Helicobacter pylori; Humans; Hydroxocobalamin; Malabsorption Syndromes; Metronidazole; Middle Aged; Neural Conduction; Omeprazole; Peripheral Nervous System Diseases; Remission Induction; Vitamin B 12 Deficiency | 1998 |
Clinical quiz. Gastrospirillum hominis.
Topics: Bacterial Infections; Bismuth; Child; Gastric Mucosa; Gastritis; Helicobacter heilmannii; Humans; Male; Metronidazole; Organometallic Compounds; Salicylates; Tetracycline | 1998 |
Clostridium difficile colitis associated with treatment of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Organometallic Compounds; Penicillins; Salicylates; Stomach Diseases | 1998 |
[Evaluation of results of surgical treatment of peptic ulcer associated with Helicobacter pylori].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Evaluation Studies as Topic; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Stomach Ulcer | 1998 |
Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistant Helicobacter pylori clinical isolates.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Synergism; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Ranitidine | 1998 |
In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Nitrofurantoin; Tetracycline | 1998 |
The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; New York City; Organometallic Compounds; Peptic Ulcer; Prisons; Ranitidine; Retrospective Studies; Salicylates; Tetracycline; Urban Health | 1998 |
Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Child; Disease Progression; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole | 1999 |
A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation.
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Delivery Systems; Helicobacter Infections; Metronidazole; Solubility; Stomach Ulcer; Tablets, Enteric-Coated; Tetracycline | 1999 |
Optimal treatment for duodenal ulcer disease: a cost-decision analysis in Malaysian patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Duodenal Ulcer; Humans; Malaysia; Metronidazole; Models, Economic; Omeprazole; Tetracycline | 1999 |
Helicobacter pylori eradication treatment reduces the severity of rosacea.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin A; Immunoglobulin G; Male; Metronidazole; Middle Aged; Organometallic Compounds; Rosacea; Treatment Outcome | 1999 |
Duodenal ulcer disease: to treat H. pylori infection or not?
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Ranitidine; Tetracycline; United States | 1992 |
Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Toxins; Bacterial Vaccines; Bismuth; Clarithromycin; Drug Therapy, Combination; Enterotoxins; Enzyme-Linked Immunosorbent Assay; Escherichia coli Proteins; Helicobacter Infections; Helicobacter pylori; Macaca mulatta; Metronidazole; Omeprazole; Organometallic Compounds; Recombinant Proteins; Salicylates; Saliva; Urease | 1999 |
Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Ranitidine; Tetracycline | 1999 |
The effect of Helicobacter pylori eradication on gastro-oesophageal reflux.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Esophagitis; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Metronidazole; Middle Aged; Oxytetracycline; Severity of Illness Index | 1999 |
Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii.
Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; Biopsy; Bismuth; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; Cat Diseases; Cats; Clarithromycin; Female; Gas Chromatography-Mass Spectrometry; Helicobacter; Helicobacter Infections; Male; Metronidazole; Polymerase Chain Reaction; Prospective Studies; Random Allocation; Ranitidine; Stomach Diseases; Tinidazole; Urea | 1999 |
Re-treatment after Helicobacter pylori eradication failure.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Treatment Failure | 1999 |
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Mixed Function Oxygenases; Omeprazole; Penicillins; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Synthesis Inhibitors; Treatment Outcome | 1999 |
[Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of Helicobacter pylori].
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; Bismuth; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; L-Lactate Dehydrogenase; Metronidazole; Omeprazole; Organometallic Compounds; Purpura, Thrombocytopenic, Idiopathic; Salicylates; Tetracycline | 1999 |
Unsuccessful treatment results in survival of less virulent genotypes of Helicobacter pylori in Colombian patients.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Chemoprevention; Colombia; Follow-Up Studies; Gastritis, Atrophic; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Penicillins; Precancerous Conditions; Salicylates; Stomach Neoplasms; Treatment Failure; Virulence | 2000 |
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Treatment Outcome; United States | 2000 |
[IgG and IgA immunoglobulins in helicobacter pylori infections of children with chronic dyspepsia before and after two week triple drug therapy].
Topics: Adolescent; Amoxicillin; Bismuth; Blotting, Western; Child; Chronic Disease; Drug Therapy, Combination; Dyspepsia; Enzyme-Linked Immunosorbent Assay; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Monitoring, Physiologic; Ranitidine; Serologic Tests | 1999 |
Single drug therapy for Helicobacter pylori infection.
Topics: Bismuth; Capsules; Drug Combinations; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tetracycline | 2000 |
Pooled analysis of Helicobacter pylori eradication regimes in Asia.
Topics: Asia; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2000 |
Strategies to treat patients with antibiotic resistant Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2000 |
[Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin].
Topics: Anti-Ulcer Agents; Bismuth; Combined Modality Therapy; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Tetracycline; Treatment Failure | 2000 |
In search of the Holy Grail of Heliocobacter pylori remedies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Humans; Metronidazole; Pilot Projects; Ranitidine; Spain | 2001 |
[In vitro antimicrobial susceptibility of Helicobacter pylori strains: isolation of strains resistant to clarithromycin].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Penicillins | 2001 |
Efficacy of Helicobacter pylori eradication therapies: a single centre observational study.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Nitroimidazoles; Ranitidine; Treatment Outcome | 2001 |
Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model.
Topics: Animals; Bismuth; Disease Models, Animal; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Mice; Mice, Inbred C57BL; Organometallic Compounds; Salicylates; Tetracycline | 2002 |
Bismuth subcitrate/metronidazole/ tetracycline--Axcan Pharma. Bismuth triple therapy--Axcan Pharma, Helicide.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compounds; Peptic Ulcer; Tetracycline | 2002 |
[Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Treatment Outcome | 2003 |
The effect of antibiotics and bismuth on fecal hydrogen sulfide and sulfate-reducing bacteria in the rat.
Topics: Animals; Antacids; Anti-Infective Agents; Bacteria; Bismuth; Ciprofloxacin; Colon; Feces; Hydrogen Sulfide; Male; Metronidazole; Rats; Rats, Sprague-Dawley; Sulfasalazine; Sulfates | 2003 |
[Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Retreatment; Tetracycline | 2004 |
[Effect of acid suppression therapy for eradicating Helicobacter pylori infection on bismuth absorption from colloidal bismuth pectin].
Topics: Amoxicillin; Animals; Antacids; Bismuth; Colloids; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Kidney; Male; Metronidazole; Pectins; Random Allocation; Rats; Rats, Sprague-Dawley | 2005 |
[The effect of Helicobacter pylori eradication therapy on bismuth absorption of colloidal bismuth subcitrate].
Topics: Absorption; Amoxicillin; Animals; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Kidney; Male; Metronidazole; Omeprazole; Organometallic Compounds; Random Allocation; Rats; Rats, Sprague-Dawley | 2005 |
[The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years].
Topics: Adult; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Tetracycline | 2005 |
How effective are quadruple therapies as first-line H. pylori eradication therapies?
Topics: Adult; Anti-Infective Agents; Australia; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Metronidazole; Netherlands; Omeprazole; Tetracycline; Treatment Outcome | 2005 |
Review of successful treatment for Helicobacter species in laboratory mice.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Infective Agents; Bismuth; DNA, Bacterial; Drug Therapy, Combination; Feces; Female; Helicobacter; Helicobacter Infections; Metronidazole; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Transgenic; Polymerase Chain Reaction; Pregnancy; Rodent Diseases | 2006 |
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Omeprazole; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure | 2006 |
Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Retrospective Studies; Salicylates; Treatment Outcome | 2006 |
What is the best first choice treatment option for Helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Humans; Medication Adherence; Metronidazole; Pantoprazole; Tetracycline | 2007 |
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Rabeprazole; Ranitidine; Tetracycline; Treatment Failure | 2006 |
Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Colombia; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metaplasia; Metronidazole; Organometallic Compounds; Precancerous Conditions; Regression Analysis; Salicylates; Smoking; Treatment Failure | 2007 |
Mucosal tear in collagenous colitis.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antidiarrheals; Biopsy; Bismuth; Budesonide; Ciprofloxacin; Colitis, Collagenous; Colonoscopy; Enema; Female; Humans; Intestinal Mucosa; Metronidazole; Middle Aged; Organometallic Compounds; Salicylates; Treatment Outcome | 2009 |
Oral and intravenous eradication of Helicobacter pylori.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Hemorrhage; Humans; Infusions, Intravenous; Male; Metronidazole; Middle Aged; Pilot Projects; Ranitidine; Treatment Outcome | 2009 |
[Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Enzyme-Linked Immunosorbent Assay; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Stomach Neoplasms; Tetracycline | 2009 |
Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy.
Topics: Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Tetracycline; Treatment Outcome | 2011 |
Ranitidine bismuth citrate in the first-line of Helicobacter pylori treatment.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 2011 |
Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Male; Metronidazole; Middle Aged; Patient Compliance; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2011 |
Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hispanic or Latino; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pilot Projects; Tetracycline; Texas; Time Factors; Treatment Outcome; Urea | 2012 |
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Failure | 2014 |
[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
Topics: Amoxicillin; Anti-Bacterial Agents; Aspirin; Bismuth; Breath Tests; Clarithromycin; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metaplasia; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Republic of Korea; Stomach Neoplasms; Tetracycline | 2013 |
Controlled synthesis of uniform BiVO4 microcolumns and advanced visible-light-driven photocatalytic activity for the degradation of metronidazole-contained wastewater.
Topics: Bismuth; Catalysis; Coloring Agents; Light; Methylene Blue; Metronidazole; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Photolysis; Vanadates; Wastewater; Water Pollutants, Chemical; X-Ray Diffraction | 2014 |
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Tetracycline; Treatment Outcome | 2015 |
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Middle Aged; Omeprazole; Penicillins; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Spain; Tetracycline; Time Factors; Treatment Outcome | 2015 |
Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bacterial; Barrett Esophagus; Bismuth; Breath Tests; Clarithromycin; Disease Management; Drug Therapy, Combination; Dyspepsia; Feces; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Italy; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms; Urea | 2015 |
Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prognosis; Salicylates; Thailand | 2015 |
The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Treatment Outcome | 2015 |
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Outcome | 2016 |
Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prevalence; Proton Pump Inhibitors; Retrospective Studies; RNA, Ribosomal, 23S; Treatment Failure; United States; Young Adult | 2016 |
[Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2016 |
Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Canada; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Salvage Therapy; Tetracycline; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Bismuth and Non-bismuth Quadruple Therapy for Helicobacter pylori Eradication: Time to Make the Switch in Clinical Practice?
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure | 2017 |
New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Urea | 2017 |
Second-line bismuth-containing quadruple therapy for
Topics: Adult; Aged; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Diabetes Mellitus, Type 2; Disease Eradication; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Republic of Korea; Retrospective Studies; Risk Factors; Tetracycline; Treatment Failure; Treatment Outcome | 2017 |
Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Capsules; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Italy; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Tablets; Tetracycline; Time Factors; Treatment Failure | 2017 |
Comment on Helicobacter pylori eradication using metronidazole.
Topics: Amoxicillin; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Moxifloxacin | 2018 |
Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study.
Topics: Anti-Bacterial Agents; Bismuth; Demography; Drug Therapy, Combination; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Retrospective Studies; Tetracycline; Treatment Outcome | 2018 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Adult; Anti-Bacterial Agents; Bacteroidetes; Bismuth; Drug Therapy, Combination; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proteobacteria; Proton Pump Inhibitors; Tetracycline; Young Adult | 2018 |
[Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tinidazole; Treatment Outcome | 2018 |
Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Risk Factors; Tetracycline; Treatment Failure | 2019 |
Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.
Topics: Aged; Bismuth; Cohort Studies; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Neurotoxicity Syndromes; Organometallic Compounds; Tetracycline; Treatment Failure | 2019 |
Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Outcome and Process Assessment, Health Care; Proton Pump Inhibitors; Retrospective Studies; Tetracycline; United States | 2019 |
Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Macrolides; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Quinolones; Tetracycline; Young Adult | 2019 |
Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Child; China; Clarithromycin; Cross-Sectional Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Prospective Studies; Proton Pump Inhibitors | 2020 |
Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
Topics: Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Disease Eradication; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Republic of Korea; Tertiary Care Centers; Tetracycline; Tetracycline Resistance | 2020 |
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Hypersensitivity; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Registries; Tetracycline | 2020 |
Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Rifabutin; Treatment Outcome | 2020 |
Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Cross-Sectional Studies; Drug Hypersensitivity; Dysbiosis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors | 2020 |
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Combinations; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Spain; Tetracycline; Treatment Outcome; Young Adult | 2020 |
Helicobacter pylori and antibiotic resistance in the pediatric population: an update from Vietnam.
Topics: Amoxicillin; Bismuth; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Probiotics; Proton Pump Inhibitors; Vietnam | 2020 |
Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome; Turkey | 2020 |
Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Health Plan Implementation; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries; Slovenia | 2021 |
Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Pilot Projects; Prospective Studies | 2021 |
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Resistance, Bacterial; Europe; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries; Tetracycline; Young Adult | 2021 |
Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Retrospective Studies; Tetracycline; Treatment Outcome; Turkey | 2021 |
Prospective comparative study of the treatment of Helicobacter pylori with antibiotic susceptibility testing-guided triple therapy compared to quadruple therapy with bismuth-metronidazole-tetracycline subcitrate.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 2021 |
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Rifabutin; Stomach Neoplasms; Sulfonamides; Tetracycline; Treatment Outcome | 2021 |
Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors | 2021 |
Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rhode Island; Rifabutin; Tetracycline; Young Adult | 2021 |
Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects.
Topics: Anti-Bacterial Agents; Benzene Derivatives; Bismuth; Cross-Over Studies; Drug Therapy, Combination; Healthy Volunteers; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Male; Metronidazole; Republic of Korea; Tetracycline | 2021 |
Clinical audit of current
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Audit; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Singapore; Treatment Outcome | 2022 |
Second-line Therapy for Helicobacter Pylori Eradication: State of the Art.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline | 2022 |
Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Poland; Proton Pump Inhibitors; Retrospective Studies | 2022 |
Electrodeposition of bismuth at a graphene modified carbon electrode and its application as an easily regenerated sensor for the electrochemical determination of the antimicrobial drug metronidazole.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Carbon; Electrochemical Techniques; Electrodes; Electroplating; Graphite; Metronidazole; Regeneration; Reproducibility of Results; Water | 2023 |
Single-capsule bismuth-based quadruple therapy as a rescue therapy for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Effects of Quadruple Therapy Combined with Probiotics on
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Motilin; Pectins; Peptic Ulcer; Probiotics; Proton Pump Inhibitors; Somatostatin; Tablets, Enteric-Coated | 2022 |
Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Retrospective Studies; Treatment Outcome | 2023 |
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries | 2023 |
Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
Topics: Amoxicillin; Anti-Bacterial Agents; Asia, Southeastern; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Physicians; Proton Pump Inhibitors; Surveys and Questionnaires | 2023 |